Pharma & CDMOKOSPI 000100595 approvals105 trials

YUHAN CORPORATION

Founded in 1926 and listed on the KOSPI in 1962, Yuhan Corporation is a comprehensive pharmaceutical company known for its innovative drug Leclaza.

As of 2026-10-11, YUHAN CORPORATION has 187 Korean MFDS device approvals, 408 Korean MFDS drug approvals, 164 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Products & technology

LeclazaInnovative new drug
Antiphlamine
Bacom-C
Duowell
Copp Syrup
Elena

Regulatory approvals

data.go.kr

408 Korean MFDS drug approvals · 1960–2026 / 187 Korean MFDS device approvals · 1999–2022

MFDS drugYuhan Peramivir Injection2026-09-29
Drug · Prescription · Approval202602907
MFDS drugLixieban Tablet 60mg(Edoxaban tosylate hydrate)2026-07-27
Drug · Prescription · Approval202602154
MFDS drugLixieban tablet 30mg(Edoxaban tosylate hydrate)2026-07-27
Drug · Prescription · Approval202602155
MFDS drugLixieban Tablet 15mg(Edoxaban tosylate hydrate)2026-07-27
Drug · Prescription · Approval202602156
MFDS drugAntiphlamine-A Lotion2026-07-10
Drug · OTC · Notification202602009
MFDS drugRapicol Power Cold Soft Capsule2026-07-09
Drug · OTC · Notification202601992
MFDS drugRapicol Power Cough Soft Capsule2026-07-02
Drug · OTC · Notification202601925
MFDS drugRapicol Power Nose Soft Capsule2026-06-09
Drug · OTC · Notification202601624
MFDS drugYuhan Vono Tablet 20mg(Vonoprazanfumarate)2026-05-12
Drug · Prescription · Approval202601373
MFDS drugYuhan Vono Tablet 10mg(Vonoprazanfumarate2026-05-12
Drug · Prescription · Approval202601374
MFDS drugMicaclo Tablet 40/6.25mg2026-03-05
Drug · Prescription · Approval202600659
MFDS drugMicaclo Tablet 40/12.5mg2026-03-05
Drug · Prescription · Approval202600660

Show 68 more

MFDS drugRabepid Tablet 20/600mg2026-02-10
Drug · Prescription · Approval202600357
MFDS drugRabepid Tablet 10/600mg2026-02-10
Drug · Prescription · Approval202600358
MFDS drugRapico Nasalspray Solution2026-01-28
Drug · OTC · Notification202600241
MFDS drugMelavely Cream2025-12-24
Drug · OTC · Notification202503383
MFDS drugYuhan Pitavano Tablet 2/145mg2025-12-17
Drug · Prescription · Approval202503295
MFDS drugTwinlow Tablet 20/2.5mg2025-12-08
Drug · Prescription · Approval202503205
MFDS drugTruvita-S Tablet2025-11-25
Drug · OTC · Notification202503064
MFDS drugTruset Tablet 20/2.5/6.25mg2025-09-30
Drug · Prescription · Approval202502587
MFDS drugContac Cold Capsule2025-08-06
Drug · OTC · Notification202502051
MFDS drugYuhan M-met XR Tablet 25/1000mg2025-07-29
Drug · Prescription · Approval202501954
MFDS drugTraduoempaXR10/5/1000mg(empagliflozin, linagliptin, metformin)2025-07-29
Drug · Prescription · Approval202501955
MFDS drugTraduoempaXR25/5/1000mg(empagliflozin, linagliptin, metformin)2025-07-29
Drug · Prescription · Approval202501956
MFDS drugYuhan Minoxpen Gel 5%(Minoxidil)2025-07-15
Drug · OTC · Notification202501797
MFDS drugAntiphlamine Cool Gel2025-06-27
Drug · OTC · Notification202501608
MFDS drugYuhan M-met XR tablet 10/1000mg2025-06-23
Drug · Prescription · Approval202501542
MFDS drugYuhan Acetaminophen Injection2025-06-19
Drug · Prescription · Approval202501526
MFDS drugAntiphlamine Coin Alpha Plaster2025-06-18
Drug · OTC · Notification202501506
MFDS drugRapicol Care Dry Syrup2025-05-28
Drug · OTC · Notification202501326
MFDS drugYuhan Megavita Solution2025-03-19
Drug · OTC · Notification202500628
MFDS drugCircle Green Tablet 240mg(Ginkgo leaf dry extract)2025-02-12
Drug · OTC · Notification202500306
MFDS drugCariforman Soft Capsule(Cucurbit Semen Oil Extract(15~25->1))2025-01-08
Drug · OTC · Notification202500072
MFDS drugXareba Tablet 13.5mg2024-12-23
Drug · Prescription · Approval202403068
MFDS drugXareba Tablet 18mg2024-12-23
Drug · Prescription · Approval202403069
MFDS drugMag-B EX Soft Capsule2024-07-29
Drug · OTC · Notification202401818
MFDS drugMovana Tablet 0.2mg(Dutasteride)2024-07-25
Drug · Prescription · Approval202401805
MFDS drugANTIPHLAMINE BIGPOWER PLASTER2024-06-14
Drug · OTC · Notification202401447
MFDS drugMegatrue Six-Three-Three tablet2024-05-02
Drug · OTC · Notification202401096
MFDS drugTraduoXR Tablet 5/1000mg(Linagliptin, Metformin hydrochloride)2024-03-29
Drug · Prescription · Approval202400691
MFDS drugAntiphlamine 40 Plaster2024-02-14
Drug · OTC · Notification202400324
MFDS drugAtorvamibe A Tablet 10/20/5mg2024-02-13
Drug · Prescription · Approval202400309
MFDS drugAtorvamibe A Tablet 10/20/10mg2024-02-13
Drug · Prescription · Approval202400310
MFDS drugAtorvamibe A Tablet 10/40/10mg2024-02-13
Drug · Prescription · Approval202400311
MFDS drugAtovamibe A Tablet 10/10/5mg2024-01-12
Drug · Prescription · Approval202400095
MFDS drugAtovamibe A Tablet 10/10/10mg2024-01-12
Drug · Prescription · Approval202400096
MFDS drugAtovamibe Tablet 10/5mg(Ezetimibe, Atorvastatin calcium trihydrate)2023-05-26
Drug · Prescription · Approval202301683
MFDS drugAtova Tablet 5mg(Atorvastatin calcium trihydrate)2023-05-18
Drug · Prescription · Approval202301595
MFDS drugMinevita V Tab.2023-04-14
Drug · OTC · Notification202301243
MFDS drugYuhan Edoxaban Tablet 30mg(Edoxaban besilate hydrate)2023-04-12
Drug · Prescription · Approval202301207
MFDS drugYuhan Edoxaban Tablet 15mg(Edoxaban besilate hydrate)2023-04-12
Drug · Prescription · Approval202301208
MFDS drugRosuvamibe10/2.5mg(Ezetimibe, Rosuvastatin calcium)2023-02-07
Drug · Prescription · Approval202300468
MFDS drugYuhan Acetaminophen Tablet 500mg2023-02-02
Drug · OTC · Notification202300437
MFDS drugYuhan Pregabalin SR tablet 75mg2022-12-30
Drug · Prescription · Approval202204702
MFDS drugMag-B Speed Double Action Solution2022-12-28
Drug · OTC · Notification202204680
MFDS drugSubsidiary: 애드파마(주)LOWROZE Tab. 10/2.5mg2022-12-21
Drug · Prescription · Approval202204606
MFDS drugYuhan Edoxaban Tablet 60mg(Edoxaban besilate hydrate)2022-12-05
Drug · Prescription · Approval202204361
MFDS drugYuhan Cetirizine Tablet2022-11-02
Drug · OTC · Notification202203978
MFDS drugRAPICOL COLD SOFTCAPSULES2022-07-20
Drug · OTC · Notification202203017
MFDS drugYuhan Evefen Soft Capsule2022-06-10
Drug · OTC · Notification202202422
MFDS drugDuowell A Plus Tablet 80/5/10/5mg2022-05-20
Drug · Prescription · Approval202202135
MFDS drugDuowell A Plus Tablet 80/20/10/5mg2022-05-20
Drug · Prescription · Approval202202136
MFDS drugDuowell A Plus Tabelt 80/10/10/5mg2022-05-20
Drug · Prescription · Approval202202137
MFDS drugDuowell A Plus Tablet 40/5/10/5mg2022-05-20
Drug · Prescription · Approval202202138
MFDS drugDuowell A Plus Tablet 40/20/10/5mg2022-05-20
Drug · Prescription · Approval202202139
MFDS drugDuowell A Plus Tablet 40/10/10/5mg2022-05-20
Drug · Prescription · Approval202202140
MFDSImplant, surgical, guide for medical use2022-05-09
Product approval · Class 2수인 22-4240 호
MFDS drugSenseday-Q Tablet2021-09-24
Drug · OTC · Notification202106628
MFDS drugDuowell Plus Tablet 80/20/10mg2021-09-24
Drug · Prescription · Approval202106630
MFDS drugDuowell Plus Tablet 80/10/10mg2021-09-24
Drug · Prescription · Approval202106631
MFDS drugDuowell Plus Tablet 80/5/10mg2021-09-24
Drug · Prescription · Approval202106632
MFDS drugDuowell Plus Tablet 40/20/10mg2021-09-24
Drug · Prescription · Approval202106633
MFDS drugDuowell Plus Tablet 40/10/10mg2021-09-24
Drug · Prescription · Approval202106634
MFDS drugDuowell Plus Tablet 40/5/10mg2021-09-24
Drug · Prescription · Approval202106635
MFDS drugRaboni-D Tablet2021-06-16
Drug · Prescription · Approval202104637
MFDS drugMag-B Max Soft Capsule2021-06-04
Drug · OTC · Notification202104379
MFDS drugMegatrue Max Tablet2021-05-03
Drug · OTC · Notification202103624
MFDS drugYuhan Metformin XR Tablet 1000mg2021-04-13
Drug · Prescription · Approval202103063
MFDS drugYuhan Rivaroxaban Tablet 20mg2021-04-13
Drug · Prescription · Approval202103076
MFDS drugYuhan Rivaroxaban Tablet 15mg2021-04-13
Drug · Prescription · Approval202103077

Showing the 80 most recent of 595 records.

Clinical trials

data.go.kr

105 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 40 · Phase 1 40 · Phase 3 11 · Phase 2 7 · Phase 1/2 4)

BioequivalenceYHP2508B2026-08-26
1 trial site
BioequivalenceYHP2508A2026-08-26
1 trial site
BioequivalenceAD-116A2026-07-30
2 trial sites
BioequivalenceAD-116A2026-07-30
2 trial sites
Phase 1YH257242026-05-29
4 trial sites
BioequivalenceYHP2508C2026-04-17
1 trial site
BioequivalenceYHP25112026-02-24
1 trial site
Phase 1AD-1162026-02-09
1 trial site
Phase 2YH353242025-10-14
12 trial sites
BioequivalenceYHP24062025-09-19
1 trial site
Phase 1AD-1162025-08-22
1 trial site
Phase 3YHP24012025-07-09
11 trial sites

Show 68 more

Phase 1/2YH323642025-04-07
4 trial sites
Bioequivalence유한세파클러건조시럽(YHP2407)2025-03-11
1 trial site
BioequivalenceYHP24062025-02-19
1 trial site
BioequivalenceYHP22052024-11-13
1 trial site
Phase 3YHP2005(NTCB01)2024-09-09
10 trial sites
Phase 3NTCB02-012024-09-09
8 trial sites
Phase 1YHP24012024-08-09
2 trial sites
Phase 1YH359952024-06-28
1 trial site
Phase 1/2YH429462024-06-12
7 trial sites
BioequivalenceYHP23052024-05-21
1 trial site
BioequivalenceYHP22052024-03-26
1 trial site
Phase 1AD-1142023-07-06
1 trial site
Phase 1AD-1142023-06-16
1 trial site
Phase 1YH353242023-05-22
11 trial sites
Extension레이저티닙 (YH25448)2023-01-04
12 trial sites
Phase 1bYH353242022-08-16
9 trial sites
Phase 1/2YH323672022-06-21
13 trial sites
BioequivalenceYHP17032022-04-07
2 trial sites
BioequivalenceYHP17032021-12-13
2 trial sites
Bioequivalence렉라자정80밀리그램 (레이저티닙, YH25448)2021-09-29
1 trial site
Phase 1YH353242021-07-16
5 trial sites
Phase 1YHD1119정2021-06-16
3 trial sites
BioequivalenceYHP18112020-06-04
1 trial site
BioequivalenceYHD1119정 300mg2020-06-02
2 trial sites
BioequivalenceYHP1807정 20밀리그램2020-05-21
2 trial sites
BioequivalenceYHP17032020-02-18
2 trial sites
BioequivalenceYHP17032020-02-18
2 trial sites
BioequivalenceYHP19062020-02-11
2 trial sites
Phase 3레이저티닙 (YH25448)2019-12-11
26 trial sites
BioequivalenceYHP1807정 20밀리그램2019-11-18
2 trial sites
BioequivalenceYHP1807 2.5밀리그램2019-11-18
2 trial sites
Phase 1YHP19032019-11-11
1 trial site
BioequivalenceAD-1032019-08-09
2 trial sites
BioequivalenceYHP18042019-06-10
2 trial sites
BioequivalenceYHP18042019-05-31
2 trial sites
BioequivalenceYHP18052018-10-29
2 trial sites
BioequivalenceYHP18042018-10-19
2 trial sites
Bioequivalence로수바미브정10/5밀리그램2018-10-01
2 trial sites
Bioequivalence로수바미브정10/20밀리그램2018-10-01
2 trial sites
Phase 1YH221622018-08-14
1 trial site
Phase 1레이저티닙 (YH25448)2018-05-25
1 trial site
Phase 1YHP16042018-04-20
1 trial site
BioequivalenceYHP17032018-01-24
2 trial sites
Phase 1YHP16042017-12-14
1 trial site
Phase 1YHP16042017-11-06
1 trial site
Phase 1YH147552017-07-19
1 trial site
BioequivalenceYHP1606캡슐60mg(덱스란소프라졸)2017-06-14
2 trial sites
Phase 1YH261362017-06-14
1 trial site
Phase 1YHP16042017-03-28
1 trial site
Phase 1YHD11192017-03-27
1 trial site
Phase 3YHP16042017-01-04
28 trial sites
Phase 1/2레이저티닙 (YH25448)2016-12-23
16 trial sites
Phase 3YHD11192016-11-25
31 trial sites
Bioequivalence오셀비어현탁용분말 6mg/mL2016-11-07
2 trial sites
Phase 3YHP17012016-10-24
15 trial sites
Phase 1YHP16042016-08-12
1 trial site
Phase 2YH1177, YH1177-D2016-06-03
20 trial sites
Phase 1YHD11192016-05-31
1 trial site
BioequivalenceYH12552016-03-24
2 trial sites
Phase 2YH235372016-02-29
12 trial sites
Phase 1YHD11192016-01-12
2 trial sites
Bioequivalence아나그렐리드캡슐0.5mg(아나그렐리드염산염)(가칭)2015-12-03
2 trial sites
Phase 3YH221622015-11-09
35 trial sites
Phase 1YH221892015-11-09
2 trial sites
Phase 2YH235372015-10-01
10 trial sites
Phase 3YH147552015-09-02
23 trial sites
Phase 2YH128522015-08-21
32 trial sites
Phase 1YH128522015-07-08
1 trial site

Showing the 80 most recent of 105 records.

Global clinical trials

ClinicalTrials.gov · sponsor-matched

Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
Phase 3 · Not yet recruiting · 2026-09 · NCT07816198
Subsidiary: 애드파마(주)A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults
Phase 1 · Not yet recruiting · 2026-08 · NCT07717775
Subsidiary: 애드파마(주)A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
Phase 1 · Not yet recruiting · 2026-07 · NCT07730567
Subsidiary: 애드파마(주)A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects
Phase 1 · Not yet recruiting · 2026-07 · NCT07717749
Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects
Phase 1 · Completed · 2026-07 · NCT07584304
Subsidiary: 애드파마(주)A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers
Phase 1 · Not yet recruiting · 2026-07 · NCT07715305
Subsidiary: 애드파마(주)A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers
Phase 1 · Not yet recruiting · 2026-07 · NCT07722871
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
Phase 1 · Completed · 2026-06 · NCT07470125
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
Phase 1 · Not yet recruiting · 2026-06 · NCT07590167
Subsidiary: 애드파마(주)Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee
Phase 2 · Not yet recruiting · 2026-06 · NCT07550231

Show 157 more trials

Subsidiary: 애드파마(주)A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults
Phase 1 · Not yet recruiting · 2026-05 · NCT07618845
Subsidiary: 애드파마(주)A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
Phase 1 · Not yet recruiting · 2026-05 · NCT07521241
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232
Phase 1 · Not yet recruiting · 2026-04 · NCT07538466
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects
Phase 1 · Not yet recruiting · 2026-04 · NCT07476157
Subsidiary: 애드파마(주)A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults
Phase 1 · Not yet recruiting · 2026-04 · NCT07385248
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Phase 2 · Recruiting · 2026-03 · NCT07415551
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects
Phase 1 · Recruiting · 2026-02 · NCT07444385
Subsidiary: 애드파마(주)A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers
Phase 1 · Completed · 2026-02 · NCT07495514
Subsidiary: 애드파마(주)Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
Phase 1 · Recruiting · 2026-01 · NCT07385235
Subsidiary: 애드파마(주)Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
Phase 1 · Not yet recruiting · 2026-01 · NCT07312799
Subsidiary: 애드파마(주)A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C
Phase 1 · Not yet recruiting · 2026-01 · NCT07312773
Subsidiary: 애드파마(주)A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
Phase 1 · Completed · 2026-01 · NCT07103278
Subsidiary: 애드파마(주)A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
Phase 1 · Not yet recruiting · 2025-12 · NCT07152873
Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects
Phase 1 · Completed · 2025-10 · NCT07265167
Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
Phase 3 · Completed · 2025-08 · NCT07111468
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282
Phase 1 · Completed · 2025-07 · NCT06858865
Subsidiary: 애드파마(주)A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Phase 1 · Completed · 2025-07 · NCT06884085
Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects
Phase 1 · Completed · 2025-06 · NCT06920719
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/2 · Recruiting · 2025-06 · NCT06975410
Subsidiary: 애드파마(주)The Food Effect on PK Characteristics and Safety Profiles of PA-111
Phase 1 · Not yet recruiting · 2025-05 · NCT06976489
Subsidiary: 애드파마(주)A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Phase 1 · Not yet recruiting · 2025-04 · NCT06916130
Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects
Phase 1 · Completed · 2025-04 · NCT06926387
Subsidiary: 애드파마(주)A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Phase 1 · Recruiting · 2025-04 · NCT06932705
Subsidiary: 애드파마(주)The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
Phase 1 · Completed · 2025-03 · NCT06902818
Subsidiary: 애드파마(주)A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
Phase 1 · Recruiting · 2025-03 · NCT06884098
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
Phase 3 · Completed · 2025-02 · NCT06747936
Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers
Phase 1 · Completed · 2025-01 · NCT06775522
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
Phase 3 · Recruiting · 2024-12 · NCT06625957
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
Phase 3 · Completed · 2024-11 · NCT06625931
Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers
Phase 1 · Completed · 2024-10 · NCT06613139
Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers
Phase 1 · Completed · 2024-10 · NCT06623526
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Phase 1/2 · Recruiting · 2024-10 · NCT06616766
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Phase 3 · Recruiting · 2024-07 · NCT06441630
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Phase 1 · Active not recruiting · 2024-07 · NCT06517914
Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers
Phase 1 · Completed · 2024-06 · NCT06359626
Subsidiary: 애드파마(주)Phase III Study to Evaluate the Efficacy and Safety of AD-209
Phase 3 · Unknown · 2024-05 · NCT06348576
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-224
Phase 3 · Completed · 2024-04 · NCT06291207
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-223
Phase 3 · Completed · 2024-02 · NCT06052748
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
Phase 4 · Active not recruiting · 2023-10 · NCT06041529
Subsidiary: 애드파마(주)A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Phase 1 · Completed · 2023-09 · NCT06025773
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
Phase 1 · Completed · 2023-08 · NCT05960708
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-209
Phase 2 · Completed · 2023-04 · NCT05631990
Subsidiary: 애드파마(주)A Study to Assess the Safety and Pharmacokinetics of AD-104-A
Phase 1 · Completed · 2023-03 · NCT05703282
An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS
Unknown · 2023-01 · NCT05835518
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
Phase 4 · Completed · 2023-01 · NCT05730621
Subsidiary: (주)에이투젠Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women
Phase 1 · Unknown · 2022-11 · NCT05587283
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases
Phase 1 · Completed · 2022-11 · NCT05564221
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/2 · Recruiting · 2022-08 · NCT05523947
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-218
Phase 3 · Recruiting · 2022-07 · NCT05400317
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation
Active not recruiting · 2022-06 · NCT06247280
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
Active not recruiting · 2022-06 · NCT06282549
Subsidiary: 애드파마(주)A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
Phase 1 · Completed · 2022-01 · NCT05202405
Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.
Phase 1 · Completed · 2021-11 · NCT05162274
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
Phase 3 · Completed · 2021-11 · NCT05131997
Subsidiary: 애드파마(주)A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Phase 1 · Completed · 2021-11 · NCT05128591
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
Phase 1 · Completed · 2021-11 · NCT05062876
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131
Phase 1 · Completed · 2021-10 · NCT04690868
A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases
Phase 1 · Completed · 2021-09 · NCT05061524
A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects
Phase 1 · Completed · 2021-07 · NCT05012436
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-208
Phase 3 · Completed · 2021-06 · NCT04825561
Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy
Phase 4 · Completed · 2021-05 · NCT04846673
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132
Phase 1 · Completed · 2021-03 · NCT04755985
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
Phase 1 · Completed · 2020-12 · NCT04622358
Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease
Phase 4 · Completed · 2020-11 · NCT06046196
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
Phase 1 · Completed · 2020-11 · NCT04600284
Subsidiary: 애드파마(주)Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Phase 3 · Completed · 2020-10 · NCT06448962
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
Phase 1 · Completed · 2020-08 · NCT04494243
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and Hypercholesterolemia
Completed · 2020-06 · NCT06293261
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112
Phase 1 · Completed · 2020-05 · NCT04375865
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
Phase 4 · Completed · 2020-05 · NCT05624853
Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg
Phase 1 · Completed · 2020-04 · NCT04316065
Subsidiary: 애드파마(주)Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
Phase 2 · Completed · 2020-02 · NCT04218552
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Phase 3 · Completed · 2020-02 · NCT04248829
BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
Phase 1 · Completed · 2020-01 · NCT05418803
Subsidiary: 애드파마(주)Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine
Phase 3 · Completed · 2020-01 · NCT04158076
Subsidiary: 애드파마(주)To Evaluate the Pharmacokinetics and Safety of AD-208
Phase 1 · Completed · 2020-01 · NCT04214808
Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers
Phase 1 · Completed · 2019-12 · NCT04225052
Subsidiary: 애드파마(주)A Study to Evaluate the Efficacy and Safety of AD-203
Phase 3 · Completed · 2019-09 · NCT04066530
Subsidiary: 애드파마(주)A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole
Phase 1 · Completed · 2019-06 · NCT03980756
Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia
Phase 4 · Completed · 2019-05 · NCT03951207
Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients
Completed · 2019-04 · NCT03823274
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
Phase 1 · Completed · 2019-02 · NCT03824171
Subsidiary: 애드파마(주)Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
Phase 3 · Completed · 2019-02 · NCT03872232
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
Phase 1 · Completed · 2018-12 · NCT03764462
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
Phase 4 · Completed · 2018-10 · NCT03597412
A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity
Phase 4 · Completed · 2018-10 · NCT03509922
Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers
Phase 1 · Completed · 2018-10 · NCT03662620
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072
Phase 1 · Completed · 2018-09 · NCT03632668
Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448
Phase 1 · Completed · 2018-07 · NCT03556436
Subsidiary: 애드파마(주)Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
Phase 1 · Completed · 2018-06 · NCT03586037
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
Phase 4 · Unknown · 2018-06 · NCT03550859
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia
Phase 4 · Unknown · 2018-04 · NCT03441516
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
Phase 4 · Completed · 2018-04 · NCT03474562
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
Phase 4 · Unknown · 2018-03 · NCT03403556
High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
Phase 4 · Completed · 2018-03 · NCT03494270
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia
Phase 4 · Completed · 2018-02 · NCT03446261
A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients
Phase 4 · Completed · 2017-10 · NCT03334916
Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension
Phase 4 · Completed · 2017-09 · NCT03267329
A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia
Phase 4 · Completed · 2017-08 · NCT03217409
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706
Phase 1 · Completed · 2017-08 · NCT03235362
Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome
Phase 4 · Completed · 2017-06 · NCT04056169
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
Phase 4 · Completed · 2017-06 · NCT03232177
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
Phase 3 · Completed · 2017-05 · NCT03103256
Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers
Phase 1 · Completed · 2017-05 · NCT03191136
Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin
Phase 1 · Completed · 2017-04 · NCT03116516
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
Phase 3 · Completed · 2017-04 · NCT03067688
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
Phase 1/2 · Completed · 2017-02 · NCT03046992
Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain
Phase 3 · Completed · 2017-02 · NCT02985216
A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome
Phase 4 · Terminated · 2016-10 · NCT02968160
A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin
Phase 1 · Completed · 2016-08 · NCT02951962
A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
Phase 1 · Completed · 2016-06 · NCT02783183
A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
Phase 1/2 · Terminated · 2016-06 · NCT02817347
A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis
Phase 2 · Completed · 2016-05 · NCT02759198
PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers
Phase 1 · Completed · 2016-01 · NCT02783638
A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.
Phase 2 · Completed · 2015-12 · NCT02585596
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Phase 3 · Completed · 2015-12 · NCT02620163
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
Phase 3 · Completed · 2015-11 · NCT02586129
PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin
Phase 1 · Terminated · 2015-11 · NCT02608242
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Phase 2 · Terminated · 2015-10 · NCT02567578
Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation
Phase 1/2 · Completed · 2015-08 · NCT02538367
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Completed · 2015-06 · NCT05862194
PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton
Phase 1 · Completed · 2015-06 · NCT02496910
Clinical Trial of YH14618 in Patients With Degenerative Disc Disease
Phase 2 · Completed · 2015-03 · NCT02320019
The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
Phase 1 · Completed · 2014-07 · NCT02233218
The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects
Phase 1 · Completed · 2014-06 · NCT02176668
Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Phase 1 · Completed · 2014-05 · NCT02152969
Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers
Phase 1 · Completed · 2014-04 · NCT02125227
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
Phase 3 · Completed · 2013-11 · NCT01914432
Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects
Phase 1 · Completed · 2013-08 · NCT01870674
PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin
Phase 1 · Completed · 2013-07 · NCT01975961
Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac
Phase 1 · Completed · 2013-07 · NCT01876615
The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects
Phase 1 · Completed · 2013-07 · NCT01921647
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
Phase 4 · Completed · 2013-02 · NCT01869881
AME Study of [14C]-YH4808 in Healthy Male Subjects
Phase 1 · Completed · 2013-01 · NCT01825707
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)
Phase 2 · Completed · 2013-01 · NCT01750437
Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis
Phase 2 · Completed · 2012-12 · NCT01538849
YH4808 Postprandial PK/PD Study in Healthy Subjects
Phase 1 · Completed · 2012-11 · NCT01761513
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer
Phase 1 · Completed · 2012-11 · NCT01992601
Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease
Phase 1/2 · Completed · 2012-05 · NCT01526330
Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects
Phase 1 · Completed · 2012-03 · NCT01657071
Food Effect on Pharmacokinetics of YH4808 in Healthy Male Subjects
Phase 1 · Completed · 2012-02 · NCT01520012
Safety and Efficacy of YH14617 in Diabetes Mellitus
Phase 2 · Completed · 2011-12 · NCT01507038
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers
Phase 1 · Completed · 2011-12 · NCT01525147
A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
Phase 2 · Completed · 2011-12 · NCT01499225
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers
Phase 1 · Completed · 2011-12 · NCT01526317
Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
Phase 1 · Completed · 2011-11 · NCT01609907
Safety and Efficacy of YHD1023 in Erectile Dysfunction
Phase 2 · Completed · 2011-11 · NCT01423370
Safety and Efficacy of YHD001 in Asthma
Phase 2 · Completed · 2011-11 · NCT01424124
Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
Phase 2 · Completed · 2011-09 · NCT01420445
Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects
Phase 1 · Completed · 2011-08 · NCT01420913
Comparative Pharmacokinetics of YH14659
Phase 1 · Completed · 2011-07 · NCT01422109
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis
Phase 3 · Completed · 2011-06 · NCT01400828
Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects
Phase 1 · Completed · 2011-04 · NCT01332890
Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044
Phase 1/2 · Completed · 2011-02 · NCT01419470
Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects
Phase 1 · Completed · 2009-11 · NCT01007019
Bioequivalence Study of Letrozole 2.5 mg Tablets
Completed · 2009-01 · NCT01084499
Early Access Program of Lazertinib in Republic of Korea
Approved for marketing · NCT04829422

R&D and key agreements

Source: DART corporate disclosure

제2, 제3의 렉라자 파이프라인 · Priority pipeline programs aimed at developing the next Leclaza-level innovative drugs are progressing as planned.

Key disclosures

KRX KIND via OpenDART

Contract단일판매ㆍ공급계약체결2026-09-15
Contract단일판매ㆍ공급계약체결2026-09-01
Capital주식소각결정2026-07-23
Contract단일판매ㆍ공급계약체결2026-05-20
Capital[기재정정]유상증자결정(종속회사의주요경영사항)2026-05-11
Contract단일판매ㆍ공급계약체결2026-05-06
Capital[기재정정]유상증자결정(종속회사의주요경영사항)2026-04-02
Capital[기재정정]유상증자결정(종속회사의주요경영사항)2026-03-04
Capital유상증자결정(종속회사의주요경영사항)2026-02-06
Capital주식소각결정2026-01-05

Show 12 more events

Publications

PubMed · affiliation-matched

A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases.
International immunopharmacology · 2026-11 · Cho YS, Ye YM, Lee SY 외 15
Preliminary Bereaved Family Satisfaction Questionnaire for Hospice Care: A Mixed-Methods Feasibility and Acceptability Study.
Journal of hospice and palliative care · 2026-09 · Yun H, Kwon S, Choi J 외 1
Indobufen-based dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and network meta-analysis.
The Journal of international medical research · 2026-09 · Gopinath A, Heo J, Fatima A 외 12
Recent Advances in Genetically Engineered Mouse Models of Melanoma: Insights into Tumor Initiation and Oncogenic Signaling Pathways.
International journal of stem cells · 2026-08 · Choi H, Lee JH, Cha HJ 외 2
Efficacy and Safety of Enzyme-Derived Deer Velvet Extract Supplementation on Adults with Chronic Fatigue: a Randomized, Placebo-Controlled, Double-Blind Trial.
Journal of microbiology and biotechnology · 2026-07 · Jamrasi P, Seo JW, Sung Y 외 10
Quality of life outcomes with a new sustained‑release pregabalin in a phase 3 trial of peripheral neuropathic pain.
Current medical research and opinion · 2026-07 · Lee S, An T, Kim S
Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.
Translational and clinical pharmacology · 2026-06 · Jang H, Khwarg J, Huh KY 외 3
Development and Evaluation of Tofacitinib Tablets with Comparative Dissolution and Pharmacokinetic Studies in Beagle Dogs.
AAPS PharmSciTech · 2026-05 · Lee D, Koo J, Jeon H 외 3
Protective effects of Lactiplantibacillus plantarum YC225 Mixture Are associated with Gut Microbiota in Vulvovaginal Candidiasis.
Journal of microbiology and biotechnology · 2026-04 · Kim HJ, Kim DG, Go SW 외 6
Dual Polarization 2 × 2 Array Ku-Band Antenna with Improved Polarization Purity.
Sensors (Basel, Switzerland) · 2026-04 · Lee TH, Nam H, Seo J 외 3

Show 154 more publications

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components.
Clinical pharmacology in drug development · 2026-03 · Lee S, Khwarg J, Bae S 외 4
Enhanced Proliferation and Activation of Natural Killer Cells by Deer Antler Velvet Extract, YC-1101, and Its Synergistic Antitumor Effects in CT26 Syngeneic Mouse Model.
Journal of medicinal food · 2026-03 · Lee JY, Lee J, Yeon D 외 9
Circularly Polarized X-Band Fan-Beam Antenna and Its Application to Offset Reflector Systems.
Sensors (Basel, Switzerland) · 2026-02 · Lee TH, Lee SG, Ryu SB 외 2
Diet-Controlled Whey Protein Supplementation: Mitigating Serum Creatine Kinase Levels After Continuous Resistance Exercise.
Journal of the American Nutrition Association · 2026-02 · Kim CB, Ahn D, Kim JB 외 3
A Mechanism-Based Multi-Level Population PK/PD Model for Potassium-Competitive Acid Blockers.
CPT: pharmacometrics & systems pharmacology · 2026-01 · Jung W, Lee J, Jeon H 외 4
Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis".
Clinical lung cancer · 2026-01 · Cho BC, Kim Y
Haematococcus pluvialis extract YHC-T-2414 mitigates exercise- induced fatigue by promoting antioxidant defense and mitochondrial biogenesis.
Frontiers in nutrition · 2026-01 · Jeong J, Jeon H, Song A 외 2
Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype.
Clinical drug investigation · 2025-12 · Mehta J, Thompson C, Scheers E 외 7
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
Clinical lung cancer · 2025-12 · Yang JC, Ahn MJ, Kim JH 외 17
Correction: Gender differences in the association between community care and quality of life among older adults in China.
Scientific reports · 2025-07 · Cui Y, Kim S, Woo S 외 1
Gender differences in the association between community care and quality of life among older adults in China.
Scientific reports · 2025-07 · Cui Y, Kim S, Woo S 외 1
Supplementation with the Probiotic Strains Bifidobacterium longum and Lactiplantibacillus rhamnosus Alleviates Glucose Intolerance by Restoring the IL-22 Response and Pancreatic Beta Cell Dysfunction in Type 2 Diabetic Mice.
Probiotics and antimicrobial proteins · 2025-04 · Kim WJ, Ryu R, Doo EH 외 6
Exploring CP Array Antenna Characteristics and Its Applications to a Deployable Structure.
Sensors (Basel, Switzerland) · 2025-04 · Lee TH, Lee KJ, Lim W 외 1
On-water accelerated sulfenylation of indole derivatives under visible light irradiation.
Organic & biomolecular chemistry · 2025-04 · Lee JS, Lee C, Jang J 외 1
Therapeutic Efficacy of YH35324 on FcεRIα-Mediated Mast Cell/Basophil Activation.
Allergy, asthma & immunology research · 2025-03 · Ryu MS, Yang EM, Ye YM 외 4
Impact of fermented foods consumption on gastrointestinal wellbeing in healthy adults: a systematic review and meta-analysis.
Frontiers in nutrition · 2025-01 · Mukherjee A, Farsi DN, Garcia-Gutierrez E 외 22
Modulated electro-hyperthermia therapy combined with Korean mistletoe extract treatment exerts a strong anti-tumor activity by enhancing cellular and humoral immune responses in mice.
Animal cells and systems · 2025-01 · Kim Y, Hur J, Hong SC 외 6
Anti-convulsant efficacy of long-acting injectable cannabidiol formulation (IVL5005) in the pentylenetetrazol-induced convulsions, with pharmacokinetic characterization.
Frontiers in pharmacology · 2025-01 · Youm S, Cha JY, Lee S 외 6
Anti-fatigue effect of an enzymatically derived deer velvet extract through muscle damage recovery and improvement of antioxidant levels.
Journal of ethnopharmacology · 2025-01 · Park KH, Park CI, Seo JW 외 6
Cannabidiol Alleviates Chronic Prostatitis and Chronic Pelvic Pain Syndrome via CB2 Receptor Activation and TRPV1 Desensitization.
The world journal of men's health · 2025-01 · Piao JJ, Kim S, Shin D 외 13
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
BMC medicine · 2024-10 · Han JY, Ahn MJ, Lee KH 외 14
Intraplantar aminoglutethimide, a P450scc inhibitor, reduced the induction of mechanical allodynia in a rat model of thrombus-induced ischemic pain.
Molecular brain · 2024-08 · Kwon SG, Choi HS, Yoon SY 외 2
Lactobacillus plantarum LPYC225 mixture partially modulates the vaginal bacterial community of Gardnerella vaginalis-infected bacterial vaginosis in mice.
Food science and biotechnology · 2024-07 · Kim HJ, Kim DG, Kang SH 외 14
Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control.
Scientific reports · 2024-06 · Jeon HL, Kwak M, Kim S 외 3
The Root Extract of Rosa multiflora Ameliorates Nonalcoholic Steatohepatitis Development via Blockade of De Novo Lipogenesis and Inflammation.
Current issues in molecular biology · 2024-06 · Kim NH, Lee SJ, Lee KJ 외 5
Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study.
Cancers · 2024-06 · Lee J, Lee H, Yoon D 외 6
Explainable prediction of problematic smartphone use among South Korea's children and adolescents using a Machine learning approach.
International journal of medical informatics · 2024-06 · Kim K, Yoon Y, Shin S
Development of a Web Application for Simulating Plasma Drug Concentrations in Patients with Zolpidem Intoxication.
Pharmaceutics · 2024-05 · Cha HJ, Han S, Pak KC 외 1
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Lung cancer (Amsterdam, Netherlands) · 2024-04 · Chul Cho B, Han JY, Hyeong Lee K 외 12
Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study.
International immunopharmacology · 2024-03 · Ye YM, Park JW, Kim SH 외 10
Correction to: Enzyme‑derived deer velvet extract activate the immune response in cyclophosphamide‑induced immunosuppressive mice.
Food science and biotechnology · 2024-03 · Baek S, Park CI, Hwang YG 외 7
Effect of YC-1102 on the Improvement of Obesity in High-Fat Diet-Induced Obese Mice.
Current issues in molecular biology · 2024-02 · Yu HY, Kim KK, Baek SH 외 11
A lanthanide-rich kilonova in the aftermath of a long gamma-ray burst.
Nature · 2024-02 · Yang YH, Troja E, O'Connor B 외 24
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Cancer research and treatment · 2024-01 · Lee KH, Cho BC, Ahn MJ 외 21
Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function.
Translational and clinical pharmacology · 2023-12 · Park M, Choi S, Han S 외 6
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-12 · Soo RA, Cho BC, Kim JH 외 20
GV16 acupoint stimulation with bee venom reduces peripheral hypersensitivity via activation of α2 adrenoceptors in a nitroglycerin-induced migraine mouse model.
Integrative medicine research · 2023-12 · Kim SJ, Yeo JH, Yoon SY 외 1
A Case Study on Community Treatment Center for Response to COVID-19 in Korea: Focusing on Surge Capacity 4S Component Analysis and Social Well-Being Perspective.
Social work in public health · 2023-11 · Chung W, Shin S, Choi E 외 1
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Diabetes & metabolism journal · 2023-11 · Moon JS, Park IR, Kim SS 외 8
Prediction of suicidal ideation in children and adolescents using machine learning and deep learning algorithm: A case study in South Korea where suicide is the leading cause of death.
Asian journal of psychiatry · 2023-10 · Shin S, Kim K
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-10 · Reungwetwattana T, Cho BC, Lee KH 외 19
Enzyme-derived deer velvet extract activate the immune response in cyclophosphamide-induced immunosuppressive mice.
Food science and biotechnology · 2023-09 · Baek S, Park CI, Hwang YG 외 7
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023-09 · Cho BC, Ahn MJ, Kang JH 외 21
Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
The world journal of men's health · 2023-07 · Shin D, Jeon SH, Piao J 외 12
Grinding Method for Phase Transformation of Glycine.
ACS omega · 2023-05 · Kang J, Kim J, Kim WS
A Metabolomics and Big Data Approach to Cannabis Authenticity (Authentomics).
International journal of molecular sciences · 2023-05 · Jadhav PD, Shim YY, Paek OJ 외 6
Cannabidiol, a Regulator of Intracellular Calcium and Calpain.
Cannabis and cannabinoid research · 2023-02 · Jeon KH, Park SH, Bae WJ 외 8
Red Ginseng Extract and γ-Aminobutyric Acid Synergistically Enhance Immunity Against Cancer Cells and Antitumor Metastasis Activity in Mice.
Journal of medicinal food · 2023-01 · Lim JS, Kim CR, Shin KS 외 2
Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) · 2023-01 · Huh KY, Lim Y, Yoon DY 외 12
Novel Herbal Therapeutic YH23537 Improves Clinical Parameters in Ligature-Induced Periodontal Disease Model in Beagle Dogs.
International journal of dentistry · 2023-01 · Shin JW, Lee ER, Noh H 외 7
The relationship between changes in the korean fertility rate and policies to encourage fertility.
BMC public health · 2022-12 · Jeong K, Yoon J, Cho HJ 외 2
Effects of Changes in Smoking Behavior of Older Adults' Oral Health.
Healthcare (Basel, Switzerland) · 2022-10 · Jeong K, Cho S, Ryu J 외 2
Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Advances in therapy · 2022-10 · Kim B, Lee J, Jang H 외 3
Glycine max Fermented by a Novel Probiotic, Bifidobacterium animalis subsp. lactis LDTM 8102, Increases Immuno-Modulatory Function.
Journal of microbiology and biotechnology · 2022-09 · Kim JH, Jeong M, Doo EH 외 7
Exploring user perspectives on a robotic arm with brain-machine interface: A qualitative focus group study.
Medicine · 2022-09 · Kim MY, Park JY, Leigh JH 외 6
A population PK-PD model of YH4808, a novel P-CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808.
CPT: pharmacometrics & systems pharmacology · 2022-09 · Chung TK, Lee HA, Lee KR 외 3
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022-04 · Cho BC, Han JY, Kim SW 외 23
A Study on the Development of a Model for Providing Traditional Korean Medicine and Welfare Services for Community Care.
Journal of pharmacopuncture · 2022-03 · Lee EJ, Lee HJ, Oh D 외 7
Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial.
The Clinical journal of pain · 2022-02 · Han KA, Lee YH, Son HS 외 13
Kimchi improves irritable bowel syndrome: results of a randomized, double-blind placebo-controlled study.
Food & nutrition research · 2022-01 · Kim HY, Park ES, Choi YS 외 4
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.
Frontiers in chemistry · 2022-01 · Kim DK, Synn CB, Yang SM 외 22
Active Aging In Long-Term Care Facilities In Korea : Beyond The Lexical Meaning.
Journal of gerontological social work · 2022-01 · Kim HJ, Shin Y, Ha JH 외 1
Study on the Improvement of Health and Nutrition Status After a 12-week Protein-Rich Supplementation Regimen in Children and Adolescents With Brain Lesions Disorder.
Clinical nutrition research · 2022-01 · Yoon H, Park HS, An X 외 6
Traditional Korean Medicine Home Care for the Older Adults during the COVID-19 Pandemic in South Korea.
International journal of environmental research and public health · 2022-01 · Sung SH, Baik YS, Han JE 외 7
Synergistic effect of Korean red ginseng extract and GABA mixture on the IgE production in mice via Th1/Th2 cell balance.
Food science and biotechnology · 2021-11 · Lim JS, Kim CR, Shin KS 외 3
Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies.
JTO clinical and research reports · 2021-10 · Jang SB, Kim KB, Sim S 외 9
Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen.
Translational and clinical pharmacology · 2021-09 · Yoon S, Oh E, Park MS 외 5
Pharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers.
Clinical therapeutics · 2021-08 · Moon SJ, Jeon JY, Lim Y 외 6
A population pharmacokinetic-pharmacodynamic model of YH12852, a highly selective 5-hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation.
CPT: pharmacometrics & systems pharmacology · 2021-08 · Kim S, Lee HA, Jang SB 외 1
Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.
Immune network · 2021-06 · Kang TG, Park HJ, Moon J 외 2
The Use of Traditional Korean Medicine (TKM) by Children: A Correlational Study between Parent's Perception and Their Children's Use Reported by Parents.
Healthcare (Basel, Switzerland) · 2021-04 · Kim J, Park JK, Park JY 외 2
Current Status of Traditional Korean Medicine Services in Public Sector: A Study for Integrating Traditional Korean Medicine into Community Care System.
Healthcare (Basel, Switzerland) · 2021-04 · Sung SH, Park M, Kim J 외 7
YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation.
Clinical and translational science · 2021-03 · Lee HA, Ju Moon S, Yoo H 외 5
Anti-obesity effect with reduced adverse effect of the co-administration of mini-tablets containing orlistat and mini-tablets containing xanthan gum: In vitro and in vivo evaluation.
International journal of pharmaceutics · 2020-12 · Kim S, Kim JH, Seok SH 외 1
Association between Relative Handgrip Strength and Osteoporosis in Older Women: The Korea National Health and Nutrition Examination Survey 2014-2018.
Annals of geriatric medicine and research · 2020-12 · Ahn KH, Lee Y, Sohn TY 외 4
Amplification of Vitamin D2 in the White Button Mushroom (Agaricus bisporus) by UV-B Irradiation and Jet-Milling for Its Potential Use as a Functional Ingredient.
Foods (Basel, Switzerland) · 2020-11 · Heo TY, Kim YN, Park IB 외 1
Current status and future perspective of external herbal dispensaries preparing traditional herbal medicine in South Korea: the first National-Wide Survey results.
BMC complementary medicine and therapies · 2020-11 · Sung SH, Han JE, Ryu JY 외 6
Ring finger protein 219 regulates inflammatory responses by stabilizing sirtuin 1.
British journal of pharmacology · 2020-10 · Hwang JS, Kim E, Hur J 외 2
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Journal of clinical hypertension (Greenwich, Conn.) · 2020-10 · Jin X, Kim MH, Han KH 외 28
Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects.
Translational and clinical pharmacology · 2020-09 · Park H, Kim CO, Kim M 외 4
Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma.
Genome biology · 2020-08 · Sa JK, Chang N, Lee HW 외 32
Risk communication for labeling all ingredients in consumer products.
Journal of toxicology and environmental health. Part A · 2020-07 · Lee BM, Choi M, Shin I 외 8
UPLC-QTOF-MS/MS screening and identification of bioactive compounds in fresh, aged, and browned Magnolia denudata flower extracts.
Food research international (Ottawa, Ont.) · 2020-07 · Joo YH, Nam MH, Chung N 외 1
The rice/maize pathogen Cochliobolus spp. infect and reproduce on Arabidopsis revealing differences in defensive phytohormone function between monocots and dicots.
The Plant journal : for cell and molecular biology · 2020-07 · Völz R, Park JY, Kim S 외 4
Effective inhibition of C3a-mediated pro-inflammatory response by a human C3a-specific protein binder.
Biotechnology and bioengineering · 2020-06 · Sohn YK, Son S, Choi Y 외 4
American consumers' perception and acceptance of an ethnic food with strong flavor: a case study of Kimchi with varying levels of red pepper and fish sauce.
Journal of the science of food and agriculture · 2020-04 · Park HJ, Ko JM, Lim J 외 1
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.
Translational and clinical pharmacology · 2020-03 · Lee WY, Oh E, Cui M 외 7
Highly bioavailable curcumin powder suppresses articular cartilage damage in rats with mono-iodoacetate (MIA)-induced osteoarthritis.
Food science and biotechnology · 2020-02 · Park HJ, Lee CK, Song SH 외 3
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
Journal of clinical hypertension (Greenwich, Conn.) · 2020-02 · Kim W, Chang K, Cho EJ 외 14
Structural and kinetic insights into flavin-containing monooxygenase and calponin-homology domains in human MICAL3.
IUCrJ · 2020-01 · Kim J, Lee H, Roh YJ 외 13
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
The Lancet. Oncology · 2019-12 · Ahn MJ, Han JY, Lee KH 외 18
Enzymatic hydrolysis increases ginsenoside content in Korean red ginseng (Panax ginseng CA Meyer) and its biotransformation under hydrostatic pressure.
Journal of the science of food and agriculture · 2019-12 · Kim HW, Han SH, Lee SW 외 3
Association of recommended food score with depression, anxiety, and quality of life in Korean adults: the 2014-2015 National Fitness Award Project.
BMC public health · 2019-07 · Lee JE, Kim YJ, Park HJ 외 3
Sulfate assimilation regulates hydrogen sulfide production independent of lifespan and reactive oxygen species under methionine restriction condition in yeast.
Aging · 2019-06 · Choi KM, Kim S, Kim S 외 8
Signaling pathways associated with macrophage-activating polysaccharides purified from fermented barley.
International journal of biological macromolecules · 2019-06 · Kim HW, Shin MS, Lee SJ 외 4
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.
The Journal of experimental medicine · 2019-05 · Shin YJ, Sa JK, Lee Y 외 14
YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2019-04 · Yun J, Hong MH, Kim SY 외 14
A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+-competitive acid blocker.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2019-03 · Lee HA, Lee KR, Jang SB 외 3
Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects.
Drug design, development and therapy · 2019-01 · Moon SJ, Jeon JY, Jang K 외 3
Perspectives on trace chemical safety and chemophobia: risk communication and risk management.
Journal of toxicology and environmental health. Part A · 2019-01 · Lee BM, Kwon S, Cho YM 외 4
Comparison of the Inhibitory Activities of 5,6-Dihydroergosterol Glycoside α- and β-Anomers on Skin Inflammation.
Molecules (Basel, Switzerland) · 2019-01 · Kim TK, Cho YK, Park H 외 2
Perspectives on trace chemical safety and chemophobia: risk communication and risk management.
Journal of toxicology and environmental health. Part A · 2019-01 · Lee BM, Kwon S, Cho YM 외 4
Effect of isomaltulose used for osmotic extraction of Prunus mume fruit juice substituting sucrose.
Food science and biotechnology · 2018-12 · Kim HW, Han SH, Lee SW 외 1
Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.
European journal of clinical pharmacology · 2018-10 · Kim E, Kim A, Yi S 외 8
Preparation and evaluation of non-effervescent gastroretentive tablets containing pregabalin for once-daily administration and dose proportional pharmacokinetics.
International journal of pharmaceutics · 2018-10 · Kim S, Hwang KM, Park YS 외 2
Notoginseng Radix and Rehmanniae Radix Preparata Extract Combination (YH23537) Reduces Pain and Cartilage Degeneration in Rats with Monosodium Iodoacetate-Induced Osteoarthritis.
Journal of medicinal food · 2018-08 · Jhun JY, Na HS, Shin JW 외 9
Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2018-06 · Jeong HR, Kim JY, Kim SN 외 1
Quality-by-design approach for the development of telmisartan potassium tablets.
Drug development and industrial pharmacy · 2018-05 · Oh GH, Park JH, Shin HW 외 2
YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.
Biomolecules & therapeutics · 2018-03 · Han T, Lee BM, Park YH 외 4
The novel, potent and highly selective 5-HT4 receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility.
British journal of pharmacology · 2018-02 · Jeong EJ, Chung SY, Hong HN 외 2
Immunoadjuvant activity in mice of polysaccharides isolated from the leaves of Panax ginseng C.A. Meyer.
International journal of biological macromolecules · 2018-02 · Hwang SH, Shin MS, Yoon TJ 외 1
Polysaccharides from ginseng leaves inhibit tumor metastasis via macrophage and NK cell activation.
International journal of biological macromolecules · 2017-10 · Shin MS, Hwang SH, Yoon TJ 외 2
YH12852, a potent and highly selective 5-HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motility in a guinea pig model of postoperative ileus.
Neurogastroenterology and motility · 2017-10 · Hussain Z, Lee YJ, Yang H 외 3
Pilot trial on separation conditions for diaper recycling.
Waste management (New York, N.Y.) · 2017-09 · Kim KS, Cho HS
A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
Alimentary pharmacology & therapeutics · 2017-08 · Yi S, Lee H, Jang SB 외 5
YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model.
Archives of pharmacal research · 2017-06 · Park YH, Choi HH, Lee DH 외 7
Changes in the antigenicity and allergenicity of ovalbumin in chicken egg white by N-acetylglucosaminidase.
Food chemistry · 2017-02 · Park HY, Yoon TJ, Kim HH 외 2
Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells.
Frontiers in pharmacology · 2017-01 · Oh YS, Seo E, Park K 외 1
Tip-loaded dissolving microneedles for transdermal delivery of donepezil hydrochloride for treatment of Alzheimer's disease.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2016-08 · Kim JY, Han MR, Kim YH 외 3
Changes in Saturday outpatient volume and billings after introducing the Saturday incentive programme to clinics in South Korea: a longitudinal cohort study using claims data from 2012 to 2014.
BMJ open · 2016-06 · Ha HJ, Han KT, Kim SJ 외 3
Growth Performance, Relative Meat and Organ Weights, Cecal Microflora, and Blood Characteristics in Broiler Chickens Fed Diets Containing Different Nutrient Density with or without Essential Oils.
Asian-Australasian journal of animal sciences · 2016-04 · Kim SJ, Lee KW, Kang CW 외 1
Identification of Selective ERRγ Inverse Agonists.
Molecules (Basel, Switzerland) · 2016-01 · Kim J, Im CY, Yoo EK 외 13
Efficacy and Safety of Modified Pranlukast (Prakanon(®)) Compared with Pranlukast (Onon(®)): A Randomized, Open-Label, Crossover Study.
The open respiratory medicine journal · 2016-01 · Kim SW, Kim H, Ryu YJ 외 4
The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Carcinogenesis · 2015-12 · Byun S, Shin SH, Lee E 외 14
Consumption of pharmaceutical drugs in exception region of separation for drug prescribing and dispensing program in South Korea.
Substance abuse treatment, prevention, and policy · 2015-09 · Yuk SM, Han KT, Kim SJ 외 5
Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways.
The Journal of biological chemistry · 2015-09 · Byun S, Lim S, Mun JY 외 10
SIGN-R1 and complement factors are involved in the systemic clearance of radiation-induced apoptotic cells in whole-body irradiated mice.
Biochemical and biophysical research communications · 2015-08 · Park JY, Loh S, Cho EH 외 9
Combined effect of body mass index and body size perception on metabolic syndrome in South Korea: results of the fifth Korea National Health and Nutrition Examination Surveys (2010-2012).
BMC public health · 2015-06 · Yoon SH, Han KT, Kim SJ 외 4
Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM.
ACS medicinal chemistry letters · 2015-03 · Park K, Lee BM, Hyun KH 외 3
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
Drug design, development and therapy · 2015-01 · Jung JA, Lee SY, Kim JR 외 4
Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study.
Clinical therapeutics · 2014-08 · Son M, Kim Y, Lee D 외 6
Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Clinical therapeutics · 2014-08 · Lee D, Roh H, Son H 외 4
Cleavage of the terminal N-acetylglucosamine of egg-white ovalbumin N-glycans significantly reduces IgE production and Th2 cytokine secretion.
Biochemical and biophysical research communications · 2014-08 · Hwang HS, Kim JY, Park H 외 6
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Bioorganic & medicinal chemistry · 2014-04 · Park K, Lee BM, Hyun KH 외 6
Porcine Splenic Hydrolysate has Antioxidant Activity in vivo and in vitro.
Korean journal for food science of animal resources · 2014-01 · Han KH, Shimada K, Hayakawa T 외 2
Phytochemicals: a multitargeted approach to gynecologic cancer therapy.
BioMed research international · 2014-01 · Farrand L, Oh SW, Song YS 외 1
Retnla overexpression attenuates allergic inflammation of the airway.
PloS one · 2014-01 · Lee MR, Shim D, Yoon J 외 5
Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction.
Nature chemical biology · 2014-01 · Kim DG, Lee JY, Kwon NH 외 32
The effects of β-glucans on cancer metastasis.
Anti-cancer agents in medicinal chemistry · 2013-06 · Yoon TJ, Koppula S, Lee KH
Inhibitory effect of chaga mushroom extract on compound 48/80-induced anaphylactic shock and IgE production in mice.
International immunopharmacology · 2013-04 · Yoon TJ, Lee SJ, Kim EY 외 4
Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Bioorganic & medicinal chemistry letters · 2013-01 · Park K, Lee BM, Kim YH 외 6
Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus.
Archives of pharmacal research · 2012-12 · Park K
Acidic pH facilitates peripheral αβmeATP-mediated nociception in rats: differential roles of P2X, P2Y, ASIC and TRPV1 receptors in ATP-induced mechanical allodynia and thermal hyperalgesia.
Neuropharmacology · 2011-03 · Seo HS, Roh DH, Kwon SG 외 6
Novel pyrimidines as acid pump antagonists (APAs).
Bioorganic & medicinal chemistry letters · 2010-10 · Yoon YA, Park CS, Cha MH 외 3
Novel 1H-pyrrolo[2,3-c]pyridines as acid pump antagonists (APAs).
Bioorganic & medicinal chemistry letters · 2010-09 · Yoon YA, Kim DH, Lee BM 외 4
An experimental study on the airlift pump with air jet nozzle and booster pump.
Journal of environmental sciences (China) · 2009-01 · Cho NC, Hwang IJ, Lee CM 외 1
Innate immune stimulation of exo-polymers prepared from Cordyceps sinensis by submerged culture.
Applied microbiology and biotechnology · 2008-10 · Yoon TJ, Yu KW, Shin KS 외 1
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Bioorganic & medicinal chemistry letters · 2008-09 · Kim E, Park CS, Han T 외 15
Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity.
Experimental & molecular medicine · 2008-02 · Song MY, Park SK, Kim CS 외 7
Synthesis of 2-(allylthio)pyrazines as a novel cancer chemopreventive agent.
Archives of pharmacal research · 2001-02 · Lee JW, Lee B, Kim ND
Acid and base catalyzed intramolecular cyclizations of N-benzoylthiocarbamoyl-acetals.
Archives of pharmacal research · 2000-04 · Lee B, Kim C, Lee JW
Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus.
FEMS microbiology letters · 2000-01 · Kim JK, Kang H, Chae JS 외 2
Effect of food on the pharmacokinetics of YH439 and its metabolites in rats.
Archives of pharmacal research · 1997-12 · Kim MK, Ahn BN, Yoo JK 외 1
Pharmacological evaluation of five novel dexamethasone heneicosoic (21) acid derivatives.
Drugs under experimental and clinical research · 1989-01 · Hong SU, Park KH, Chae JS 외 3

Patents

KIPRIS · applicant-matched

신규의 2,3-다이하이드로-1H-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
Published · 2026-07 · Application 1020260133359
Subsidiary: (주)에이투젠ANTITUMOR OR TUMOR METASTASIS-INHIBITING COMPOSITION CONTAINING LACTOBACILLUS REUTERI ATG-F4 STRAIN AS ACTIVE INGREDIENT
PCT · Published · 2026-01 · Application PCT/KR2026/095022
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US · Published · 2025-12 · Application 19418159
Subsidiary: (주)테라베스트NK CELLS WITH IMPROVED ABILITY TO TARGET AND KILL CANCER CELLS AND USE THEREOF
PCT · Published · 2025-11 · Application PCT/KR2025/019951
암로디핀 또는 이의 염 및 클로르탈리돈 또는 이의 염을 포함하는 다층 정제 형태의 약학 조성물
Published · 2025-09 · Application 1020250135877
GLP-1 수용체 효능제 활성을 가진 벤즈이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도
Published · 2025-08 · Application 1020250120517
GLP-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도
Published · 2025-08 · Application 1020250120518
BENZIMIDAZOLE COMPOUNDS HAVING GLP-1 RECEPTOR AGONIST ACTIVITY, METHODS FOR PREPARING SAME, AND MEDICAL USES THEREOF
PCT · Published · 2025-08 · Application PCT/KR2025/013104
THIENOIMIDAZOLE COMPOUNDS HAVING GLP-1 RECEPTOR AGONIST ACTIVITY, METHODS FOR PREPARING SAME, AND MEDICAL USES THEREOF
PCT · Published · 2025-08 · Application PCT/KR2025/013105
보노프라잔 또는 이의 약학적으로 허용가능한 염을 함유하는 약학 조성물
Published · 2025-07 · Application 1020250100844

Show 539 more patents

바이사이클릭 융합환 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Published · 2025-07 · Application 1020250100760
BICYCLIC FUSED-RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
PCT · Published · 2025-07 · Application PCT/KR2025/011014
아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
Published · 2025-07 · Application 1020250093917
클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법
Published · 2025-07 · Application 1020250091993
Subsidiary: 애드파마(주)A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN PARTICLES WITH IMPROVED BIOAVAILABILITY
PCT · Published · 2025-06 · Application PCT/KR2025/007569
암의 예방 또는 치료용 약제학적 조성물
Published · 2025-05 · Application 1020250069980
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER
PCT · Published · 2025-05 · Application PCT/KR2025/007293
담도암의 치료를 위한 항-HER2/항-4-1BB 이중 특이 항체
Published · 2025-04 · Application 1020250042813
ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY FOR TREATMENT OF BILIARY TRACT CANCER
PCT · Published · 2025-04 · Application PCT/KR2025/004355
Subsidiary: (주)에이투젠COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6
US · Published · 2025-03 · Application 19090071
mRNA에 합성 테일을 도입하는 방법
Published · 2025-02 · Application 1020250026603
항-TIGIT/항-PD-L1 이중특이적 항체 및 이의 용도
Published · 2025-02 · Application 1020250026237
Anti-TIGIT/anti-PD-L1 bispecific antibody and use thereof
TW · Published · 2025-02 · Application 114107444
ANTI-TIGIT/ANTI-PD-L1 BISPECIFIC ANTIBODY AND USE THEREOF
PCT · Published · 2025-02 · Application PCT/KR2025/002780
Subsidiary: (주)에이투젠COMPOSITION FOR ALLEVIATING MALE MENOPAUSE SYMPTOMS CONTAINING PROBIOTICS
PCT · Published · 2025-02 · Application PCT/KR2025/002597
고셔병의 예방 또는 치료용 약제학적 조성물
Published · 2025-01 · Application 1020250010599
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GAUCHER DISEASE
PCT · Published · 2025-01 · Application PCT/KR2025/001353
Subsidiary: (주)테라베스트EXTRACELLULAR VESICLES DERIVED FROM HEMATOPOIETIC STEM CELLS OR NATURAL KILLER CELLS AND USE THEREOF
PCT · Published · 2024-12 · Application PCT/KR2024/020076
Subsidiary: (주)테라베스트COMPOSITION COMPRISING MIXTURE OF EXOSOMES AS ACTIVE INGREDIENT AND USE THEREOF
PCT · Published · 2024-12 · Application PCT/KR2024/020081
Subsidiary: (주)에이투젠COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CACHEXIA, COMPRISING LACTOBACILLUS REUTERI ATG-F4 STRAIN
PCT · Published · 2024-10 · Application PCT/KR2024/016494
DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US · Published · 2024-10 · Application 18919743
7,7-다이메틸푸로[3,4-b]피리딘-5(7H)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Published · 2024-10 · Application 1020240138098
피라졸로[3,4-b]피리딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Published · 2024-10 · Application 1020240138104
7,7-DIMETHYLFURO[3,4-B]PYRIDIN-5(7H)-ONE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
PCT · Published · 2024-10 · Application PCT/KR2024/096314
PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
PCT · Published · 2024-10 · Application PCT/KR2024/015346
Subsidiary: (주)유한건강생활SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING NEUROLOGICAL DISORDERS, AND METHOD FOR PREPARING SAME
EP · Published · 2024-07 · Application 24860519.8
Subsidiary: (주)유한건강생활SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING NEUROLOGICAL DISORDERS, AND METHOD FOR PREPARING SAME
PCT · Published · 2024-07 · Application PCT/KR2024/095928
피리미딘 및 피리딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Published · 2024-06 · Application 1020240073459
Pyrimidine/pyridine derivatives or salts thereof and pharmaceutical compositions comprising the same
TW · Published · 2024-06 · Application 113120780
PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
PCT · Published · 2024-06 · Application PCT/KR2024/007677
이중 작용 단백질 및 이를 포함하는 약학적 조성물
Registered · 2024-05 · Application 1020240065441
Subsidiary: (주)유한건강생활COMPOSITION CONTAINING MIXTURE OF HEMP STEM AND ROOT EXTRACT AS ACTIVE INGREDIENT FOR SKIN SOOTHING EFFECT
PCT · Published · 2024-04 · Application PCT/KR2024/005340
Subsidiary: (주)테라베스트ACTIVATED NATURAL KILLER CELL AND USE THEEROF
PCT · Published · 2024-03 · Application PCT/KR2024/004068
EGFR 억제제로서의 마크로시클릭 아미노피리딘 화합물
Published · 2024-02 · Application 1020257030856
EGFR 억제제로서의 마크로시클릭 아미노피리딘 화합물
Published · 2024-02 · Application 1020257030863
EGFR 억제제로서의 마크로시클릭 아미노피리딘 화합물
Published · 2024-02 · Application 1020257030861
Macrocyclic aminopyridine compounds as EGFR inhibitors
TW · Published · 2024-02 · Application 113106201
Macrocyclic aminopyridine compounds as EGFR inhibitors
TW · Published · 2024-02 · Application 113106202
MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
EP · Published · 2024-02 · Application 24760548.8
MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
EP · Published · 2024-02 · Application 24760551.2
MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
EP · Published · 2024-02 · Application 24760549.6
MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
PCT · Published · 2024-02 · Application PCT/KR2024/002202
MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
PCT · Published · 2024-02 · Application PCT/KR2024/002206
Antigen Binding Proteins that Bind PD-L1
US · Published · 2024-01 · Application 18412102
아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
Registered · 2023-12 · Application 1020230184208
Subsidiary: (주)테라베스트FUSION PROTEIN COMPRISING CD137 EXTRACELLULAR DOMAIN, IMMUNE CELLS EXPRESSING SAME, AND USE THEREOF
PCT · Published · 2023-11 · Application PCT/KR2023/019470
이중 작용 단백질 및 이의 용도
Published · 2023-11 · Application 1020230159815
DUAL FUNCTION PROTEINS AND USES THEREOF
EP · Published · 2023-11 · Application 23892068.0
다이메틸-2,3-다이하이드로-1H-인덴 유도체의 신규 염 및 이의 제조방법
Published · 2023-10 · Application 1020230141682
다이메틸-2,3-다이하이드로-1H-인덴 유도체의 개선된 제조방법
Published · 2023-10 · Application 1020230141697
NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME
EP · Published · 2023-10 · Application 23883023.6
IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES
EP · Published · 2023-10 · Application 23883025.1
IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES
PCT · Published · 2023-10 · Application PCT/KR2023/016442
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US · Published · 2023-10 · Application 18491616
Subsidiary: (주)유한건강생활SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING SAME
US · Published · 2023-10 · Application 19119600
Subsidiary: (주)유한건강생활SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING SAME
EP · Published · 2023-10 · Application 23880158.3
Subsidiary: (주)유한건강생활SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING SAME
PCT · Published · 2023-10 · Application PCT/KR2023/015992
Subsidiary: (주)테라베스트PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING NATURAL KILLER CELLS AND TOPOISOMERASE INHIBITOR AS ACTIVE INGREDIENTS
PCT · Published · 2023-10 · Application PCT/KR2023/015593
프로테인 카이네이즈에 대한 선택적 억제제의 합성에 유용한 중간체 및 이의 제조방법
Registered · 2023-09 · Application 1020230126377
Subsidiary: (주)유한건강생활FOOD COMPOSITION USING ENZYMATIC DECOMPOSITION EXTRACT OF ANTLERS (HENKIV®) FOR ATHLETIC PERFORMANCE ENHANCEMENT OR RECOVERY FROM FATIGUE
PCT · Published · 2023-08 · Application PCT/KR2023/012630
Subsidiary: (주)테라베스트COMPOSITION COMPRISING NATURAL KILLER CELL-DERIVED EXOSOME AND BIOCOMPATIBLE POLYMER AS ACTIVE INGREDIENTS, AND USE THEREOF
PCT · Published · 2023-08 · Application PCT/KR2023/012553
Subsidiary: (주)테라베스트COMPOSITION COMPRISING INDUCED PLURIPOTENT STEM CELL-DERIVED EXOSOMES AND COLLAGEN AS ACTIVE INGREDIENTS, AND USES THEREOF
PCT · Published · 2023-08 · Application PCT/KR2023/012557
Subsidiary: (주)테라베스트COMPOSITION COMPRISING HUMAN CELL-DERIVED MICROVESICLES AND HYALURONIC ACID OR COLLAGEN, AND USE THEREOF
PCT · Published · 2023-08 · Application PCT/KR2023/012559
Subsidiary: (주)유한건강생활COMBINED ADMINISTRATION PHARMACEUTICAL COMPOSITION COMPRISING, AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER, ENZYMATIC DEGRADATION EXTRACT OF DEER ANTLER ENHANCING ACTIVITY OF IMMUNE CELLS INCLUDING NK CELLS AND IMMUNOTHERAPEUTIC ANTICANCER AGENT
PCT · Published · 2023-05 · Application PCT/KR2023/007320
HER2 저발현 암의 치료 또는 예방용 약학적 조성물
Published · 2023-04 · Application 1020230045920
PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER WITH LOW EXPRESSION LEVEL OF HER2
EP · Published · 2023-04 · Application 23785034.2
Subsidiary: (주)테라베스트NATURAL KILLER CELLS PRODUCED FROM INDUCED PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND USE THEREOF
US · Published · 2023-03 · Application 18852071
Subsidiary: (주)테라베스트NATURAL KILLER CELLS PRODUCED FROM INDUCED PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND USE THEREOF
EP · Published · 2023-03 · Application 23781446.2
Subsidiary: (주)테라베스트NATURAL KILLER CELLS PRODUCED FROM INDUCED PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND USE THEREOF
PCT · Published · 2023-03 · Application PCT/KR2023/004404
Subsidiary: (주)테라베스트PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING NATURAL KILLER CELL
US · Published · 2023-03 · Application 18849153
Subsidiary: (주)테라베스트PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING NATURAL KILLER CELL
EP · Published · 2023-03 · Application 23775297.7
Subsidiary: (주)테라베스트PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING NATURAL KILLER CELL
PCT · Published · 2023-03 · Application PCT/KR2023/003782
Subsidiary: (주)유한건강생활COMPOSITION CONTAINING BRIER TREE ROOT EXTRACT FOR ALLEVIATION, PREVENTION, OR TREATMENT OF OBESITY AND METABOLIC DISEASES
PCT · Published · 2022-12 · Application PCT/KR2022/021566
METHOD FOR PRODUCING DUAL FUNCTION PROTEINS AND ITS DERIVATIVES
US · Published · 2022-12 · Application 18068506
암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합
Published · 2022-11 · Application 1020220153645
바이사이클릭 융합환 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Published · 2022-09 · Application 1020220124299
BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP · Published · 2022-09 · Application 22876896.6
Subsidiary: (주)테라베스트NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF
PCT · Published · 2022-09 · Application PCT/KR2022/014034
EGFR 억제제로서의 치환된 아미노피리딘 화합물
Published · 2022-08 · Application 1020247009721
EGFR 억제제로서의 6-원 헤테로아릴-함유 아미노피리딘 화합물
Published · 2022-08 · Application 1020247009716
SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
EP · Published · 2022-08 · Application 22861726.2
SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
PCT · Published · 2022-08 · Application PCT/KR2022/012696
5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
TW · Published · 2022-08 · Application 111131847
Substituted aminopyridine compounds as EGFR inhibitors
TW · Published · 2022-08 · Application 111131849
6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
TW · Published · 2022-08 · Application 111131848
SIRP-ALPHA 변이체 및 이의 용도
Withdrawn · 2022-07 · Application 1020220089057
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS PARACASEI ATG-E1 STRAIN OR COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE
US · Published · 2022-06 · Application 18580997
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS PARACASEI ATG-E1 STRAIN OR COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE
EP · Published · 2022-06 · Application 22846047.3
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS PARACASEI ATG-E1 STRAIN OR COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE
PCT · Published · 2022-06 · Application PCT/KR2022/008333
Subsidiary: 에스비바이오팜(주)하부 요로계 애완동물 소프트사료의 제조방법
Registered · 2022-06 · Application 1020220067663
OX40 작용제 및 그의 용도
Published · 2022-05 · Application 1020220065533
GDF15 변이체 및 GLP-1 수용체 작용제를 포함하는 병용 투여용 조성물
Abandoned · 2022-05 · Application 1020220062115
GDF15 변이체를 포함하는 비알코올성 지방간질환 또는 비알코올성 지방간염의 예방 또는 치료용 조성물
Abandoned · 2022-05 · Application 1020220062116
COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST
EP · Published · 2022-05 · Application 22805032.4
COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT
EP · Published · 2022-05 · Application 22805036.5
COMPOSITION FOR COMBINATION THERAPY COMPRISING GROWTH DIFFERENTIATION FACTOR-15 VARIANT AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST
PCT · Published · 2022-05 · Application PCT/KR2022/007242
글루코실세라마이드 합성효소에 대한 저해 활성을 갖는 신규의 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
Published · 2022-05 · Application 1020220057000
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US · Published · 2022-05 · Application 18559466
NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP · Published · 2022-05 · Application 22807764.0
트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
Published · 2022-04 · Application 1020237038359
Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same
TW · Published · 2022-04 · Application 111115157
TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP · Published · 2022-04 · Application 22791234.2
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS FERMENTUM ATG-V5 STRAIN, OR COMPOSITION FOR ENHANCING IMMUNITY COMPRISING SAME
US · Published · 2022-04 · Application 18288640
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS FERMENTUM ATG-V5 STRAIN, OR COMPOSITION FOR ENHANCING IMMUNITY, COMPRISING SAME
EP · Registered · 2022-04 · Application 22796012.7
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS FERMENTUM ATG-V5 STRAIN, OR COMPOSITION FOR ENHANCING IMMUNITY, COMPRISING SAME
PCT · Published · 2022-04 · Application PCT/KR2022/005413
신규의 인돌아민 2,3-디옥시게나아제 저해제, 이의 제조방법, 및 이를 포함하는 약학 조성물
Published · 2022-03 · Application 1020220035127
NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US · Published · 2022-03 · Application 18551894
NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP · Published · 2022-03 · Application 22776033.7
항-4-1BB/항-HER2 이중특이적 항체의 정제방법
Published · 2022-01 · Application 1020220008861
METHODS FOR PURIFYING AN ANTI-4-1BB/ANTI-HER2 BISPECIFIC ANTIBODY
US · Published · 2022-01 · Application 18273888
METHODS FOR PURIFYING AN ANTI-4-1BB/ANTI-HER2 BISPECIFIC ANTIBODY
PCT · Published · 2022-01 · Application PCT/KR2022/001083
Subsidiary: (주)유한건강생활IMMUNO-POTENTIATING ENZYMATIC EXTRACT OF DEER ANTLER THAT EXCELLENTLY ENHANCES ACTIVITY OF IMMUNE CELL INCLUDING NK CELL
US · Published · 2021-12 · Application 18259738
Subsidiary: (주)유한건강생활IMMUNO-POTENTIATING ENZYMATIC EXTRACT OF DEER ANTLER THAT EXCELLENTLY ENHANCES ACTIVITY OF IMMUNE CELL INCLUDING NK CELL
EP · Published · 2021-12 · Application 21915814.4
Subsidiary: (주)유한건강생활IMMUNO-POTENTIATING ENZYMATIC EXTRACT OF DEER ANTLER THAT EXCELLENTLY ENHANCES ACTIVITY OF IMMUNE CELL INCLUDING NK CELL
PCT · Published · 2021-12 · Application PCT/KR2021/020127
Subsidiary: (주)에이투젠Lactobacillus plantarum strain ATG-K2, ATG-K6 or ATG-K8, and composition for preventing or treating vaginitis comprising same
US · Registered · 2021-11 · Application 17527002
생체이용율이 개선된 페노피브레이트 입자를 포함하는 약제학적 조성물
Registered · 2021-09 · Application 1020210128965
Subsidiary: 애드파마(주)A PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRATE PARTICLES WITH IMPROVED BIOAVAILABILITY
PCT · Published · 2021-09 · Application PCT/KR2021/013371
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US · Published · 2021-09 · Application 17478600
DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US · Published · 2021-09 · Application 17478628
Subsidiary: 애드파마(주)CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS IN A MONOLITHIC MATRIX TABLET FORM COMPRISING REBAMIPIDE AND PROCESSES FOR PREPARING THE SAME
PCT · Published · 2021-09 · Application PCT/KR2021/011713
Subsidiary: 애드파마(주)PHARMACEUTICAL COMPOSITIONS IN A TABLET FORM COMPRISING OMEPRAZOLE, ESOMEPRAZOLE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PROCESSES FOR PREPARING THE SAME
PCT · Published · 2021-09 · Application PCT/KR2021/011714
Controlled release pharmaceutical compositions in a monolithic matrix tablet form comprising rebamipide and processes for preparing the same
TW · Registered · 2021-08 · Application 110132046
Pharmaceutical compositions in a tablet form comprising omeprazole, esomeprazole, or a pharmaceutically acceptable salt thereof and processes for preparing the same
TW · Registered · 2021-08 · Application 110132047
Subsidiary: (주)네오딘바이오벳시설 내 병원체 감염진단 및 방역관리 시스템
Registered · 2021-08 · Application 1020210102709
Subsidiary: (주)테라베스트CELL THERAPEUTIC COMPOSITION COMPRISING T MEMORY STEM CELLS DEDIFFERENTIATED FROM TUMOR-INFILTRATING LYMPHOCYTES, AND METHOD FOR PRODUCING COMPOSITION
PCT · Published · 2021-08 · Application PCT/KR2021/010183
Subsidiary: 에스비바이오팜(주)종양 처방식 애완동물 소프트사료의 제조방법
Registered · 2021-07 · Application 1020210088771
Subsidiary: 에스비바이오팜(주)생고기를 활용한 애완동물 소프트사료의 제조방법
Registered · 2021-07 · Application 1020210087648
트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물
Withdrawn · 2021-04 · Application 1020210052441
LAG3에 결합하는 조작된 항체
Published · 2021-04 · Application 1020227038511
Subsidiary: (주)테라베스트Nanoparticle comprising drug dimer and use thereof
TW · Registered · 2021-03 · Application 110111207
Subsidiary: (주)테라베스트NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF
US · Published · 2021-03 · Application 17907252
Subsidiary: (주)테라베스트NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF
EP · Published · 2021-03 · Application 21776705.2
Subsidiary: (주)테라베스트NANOPARTICLES COMPRISING DRUG DIMERS, AND USE THEREOF
PCT · Published · 2021-03 · Application PCT/KR2021/003765
Subsidiary: (주)에이투젠COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6
US · Published · 2021-01 · Application 17996501
Subsidiary: (주)에이투젠COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6
EP · Published · 2021-01 · Application 21792617.9
Subsidiary: (주)에이투젠COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6
PCT · Published · 2021-01 · Application PCT/KR2021/001255
글리세로인산마그네슘을 포함하는 경구투여용 수성 용액 형태의 약학 조성물
Registered · 2021-01 · Application 1020210005056
라록시펜 염산염을 포함하는 약학 조성물
Registered · 2020-12 · Application 1020200186934
Subsidiary: (주)테라베스트IMMUNE CELLS HAVING NANOSTRUCTURE ATTACHED THERETO
PCT · Published · 2020-12 · Application PCT/KR2020/019375
지속형 GDF15 융합 단백질 및 이를 포함하는 약학 조성물
Published · 2020-11 · Application 1020200160013
LONG-ACTING GDF15 FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US · Published · 2020-11 · Application 17779932
글루코실세라마이드 합성효소에 대한 저해 활성을 갖는 신규의 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
Published · 2020-11 · Application 1020200150793
신규의 2,3-다이하이드로-1H-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
Registered · 2020-11 · Application 1020200150785
신규의 1,2,3,4-테트라하이드로나프탈렌 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
Registered · 2020-11 · Application 1020200150789
DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP · Registered · 2020-11 · Application 20887669.8
DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP · Registered · 2020-11 · Application 24163536.6
NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
PCT · Published · 2020-11 · Application PCT/KR2020/015864
피롤리딘 및 피페리딘 화합물
Registered · 2020-11 · Application 1020227018913
Pyrrolidine and piperidine compounds
TW · Published · 2020-11 · Application 109138557
Subsidiary: (주)테라베스트SURFACE-MODIFIED EXTRACELLULAR VESICLE AND COMPOSITION COMPRISING SAME
PCT · Published · 2020-09 · Application PCT/KR2020/012347
오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법
Registered · 2020-09 · Application 1020200113000
레바미피드를 포함하는 단일 매트릭스 정제 형태의 방출-제어형 약학 조성물 및 이의 제조방법
Registered · 2020-09 · Application 1020200112990
EGFR変異型キナーゼ活性をモジュレートするための化合物および組成物
JP · Published · 2020-08 · Application 32141205
항-EGFR/항-4-1BB 이중 특이 항체 및 이의 용도
Published · 2020-07 · Application 1020227006641
항-HER2/항-4-1BB 이중 특이 항체 및 이의 용도
Registered · 2020-07 · Application 1020227006642
항-HER2/항-4-1BB 이중 특이 항체 및 이의 용도
Published · 2020-07 · Application 1020257019038
Anti-HER2/anti-4-1BB bispecific antibody and use thereof
US · Registered · 2020-07 · Application 16939536
다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
Published · 2020-07 · Application 1020200084595
(3R,4R)-1-벤질-N,4-디메틸피페리딘-3-아민 또는 이의 염의 제조방법 및 이를 이용한 토파시티닙의 제조방법
Registered · 2020-04 · Application 1020200040725
Subsidiary: (주)테라베스트CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME
CN · Published · 2020-03 · Application 202080021396.1
Subsidiary: (주)테라베스트CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME
US · Published · 2020-03 · Application 17438603
Subsidiary: (주)테라베스트CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME
EP · Published · 2020-03 · Application 20773069.8
Subsidiary: (주)테라베스트CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME
PCT · Published · 2020-03 · Application PCT/KR2020/003577
Subsidiary: (주)유한건강생활BEER YEAST EXTRACT CONTAINING HIGH AMOUNTS OF VITAMINS B1 AND B2, AND PREPARATION METHOD THEREFOR
PCT · Published · 2020-01 · Application PCT/KR2020/000324
Subsidiary: (주)테라베스트Ultrafine iron oxide nanoparticle-based magnetic resonance imaging T1 contrast agent
CN · Published · 2019-12 · Application 201980094668.8
Subsidiary: (주)테라베스트ULTRAFINE IRON OXIDE NANOPARTICLE-BASED MAGNETIC RESONANCE IMAGING T1 CONTRAST AGENT
US · Published · 2019-12 · Application 17437353
Subsidiary: (주)테라베스트ULTRAFINE IRON OXIDE NANOPARTICLE-BASED MAGNETIC RESONANCE IMAGING T1 CONTRAST AGENT
EP · Published · 2019-12 · Application 19921364.6
Subsidiary: (주)에이투젠COMPOSITION COMPRISING LACTOBACILLUS REUTERI ATG-F4 FOR PREVENTION OR TREATMENT OF MUSCULAR DISORDER
CN · Published · 2019-12 · Application 201980095840.1
Subsidiary: (주)에이투젠Composition comprising Lactobacillus reuteri ATG-F4 for prevention or treatment of muscular disorder
US · Registered · 2019-12 · Application 17605391
Subsidiary: (주)에이투젠COMPOSITION COMPRISING LACTOBACILLUS REUTERI ATG-F4 FOR PREVENTION OR TREATMENT OF MUSCULAR DISORDER
EP · Registered · 2019-12 · Application 19940083.9
Subsidiary: (주)에이투젠COMPOSITION COMPRISING LACTOBACILLUS REUTERI ATG-F4 FOR PREVENTION OR TREATMENT OF MUSCULAR DISORDER
PCT · Published · 2019-12 · Application PCT/KR2019/017674
3,3-디플루오로알릴아민 또는 그의 염 및 그를 포함하는 제약 조성물
Registered · 2019-12 · Application 1020217021567
3,3-디플루오로알릴아민 또는 그의 염 및 그를 포함하는 제약 조성물
Registered · 2019-12 · Application 1020237043142
트리아졸로피리딘-3-온 또는 그의 염 및 그를 포함하는 제약 조성물
Abandoned · 2019-12 · Application 1020217021609
3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
TW · Registered · 2019-12 · Application 108144790
Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
TW · Published · 2019-12 · Application 108144720
아미노피리미딘 유도체 또는 이의 염을 포함하는 경구 투여용 약학 조성물
Published · 2019-10 · Application 1020257002203
아미노피리미딘 유도체 또는 이의 염을 포함하는 경구 투여용 약학 조성물
Registered · 2019-10 · Application 1020217014600
Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
TW · Registered · 2019-10 · Application 108137395
(E)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 화합물의 제조방법
Registered · 2019-07 · Application 1020217003132
암로디핀 또는 이의 염 및 클로르탈리돈 또는 이의 염을 포함하는 다층 정제 형태의 약학 조성물
Registered · 2019-06 · Application 1020190071599
Subsidiary: (주)에이투젠Novel bifidobacterium longum strain or cosmetic composition comprising same
CN · Published · 2019-06 · Application 201980095232.0
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS REUTERI ATG-F4 STRAIN HAVING FUNCTION OF ENHANCING DOPAMINE SECRETION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF PSYCHOPATHY
CN · Published · 2019-06 · Application 201980076219.0
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS PLANTARUM STRAIN ATG-K2, ATG-K6 OR ATG-K8, AND COMPOSITION FOR PREVENTING OR TREATING VAGINITIS COMPRISING SAME
CN · Published · 2019-06 · Application 201980036590.4
Subsidiary: (주)에이투젠Lactobacillus reuteri ATG-F4 strain having function of enhancing dopamine secretion and pharmaceutical composition comprising same for prevention or treatment of psychopathy
US · Registered · 2019-06 · Application 17050971
Subsidiary: (주)에이투젠NOVEL BIFIDOBACTERIUM LONGUM STRAIN OR COSMETIC COMPOSITION COMPRISING SAME
US · Published · 2019-06 · Application 17600650
Subsidiary: (주)에이투젠Lactobacillus plantarum strain ATG-K2, ATG-K6 or ATG-K8, and composition for preventing or treating vaginitis comprising same
US · Registered · 2019-06 · Application 17051007
Subsidiary: (주)에이투젠NOVEL BIFIDOBACTERIUM LONGUM STRAIN OR COSMETIC COMPOSITION COMPRISING SAME
PCT · Published · 2019-06 · Application PCT/KR2019/006938
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS REUTERI ATG-F4 STRAIN HAVING FUNCTION OF ENHANCING DOPAMINE SECRETION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF PSYCHOPATHY
PCT · Published · 2019-06 · Application PCT/KR2019/006937
Subsidiary: (주)에이투젠NOVEL LACTOBACILLUS PLANTARUM STRAIN ATG-K2, ATG-K6 OR ATG-K8, AND COMPOSITION FOR PREVENTING OR TREATING VAGINITIS COMPRISING SAME
PCT · Published · 2019-06 · Application PCT/KR2019/006936
EGFR変異型キナーゼ活性をモジュレートするための化合物および組成物
JP · Registered · 2019-04 · Application 31085608
Subsidiary: (주)유한건강생활WHOLE GINSENG COMPOSITION USING GINSENG ROOTS, LEAVES AND BERRIES AND METHOD OF PREPARING THE SAME
US · Published · 2019-03 · Application 17041081
Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same
TW · Registered · 2019-03 · Application 108109844
Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
TW · Registered · 2019-03 · Application 108109864
신규한 아릴 또는 헤테로아릴 트리아졸론 유도체 또는 그의 염, 또는 그를 포함하는 제약 조성물
Rejected · 2019-03 · Application 1020207029749
신규한 트리아졸론 유도체 또는 그의 염, 및 그를 포함하는 제약 조성물
Registered · 2019-03 · Application 1020207029750
신규 항-TIGIT 항체 및 그의 용도
Registered · 2019-02 · Application 1020190023921
덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
Registered · 2019-02 · Application 1020190015113
신규의 3,3-다이플루오로알릴아민 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2018-12 · Application 1020180161725
트라이아졸로피리딘-3-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2018-12 · Application 1020180161732
아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
Withdrawn · 2018-10 · Application 1020180124171
베이킹 소다를 함유하는 칫솔모 및 그 칫솔모를 포함하는 칫솔
Rejected · 2018-08 · Application 1020180103276
소라페닙 헤미캄실산 염 및 이의 제조 방법
Rejected · 2018-08 · Application 1020180096220
갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
Registered · 2018-07 · Application 1020180086437
아미노피리미딘 유도체의 개선된 제조방법
Registered · 2018-07 · Application 1020180086376
아미노피리미딘 유도체의 합성에 유용한 신규의 중간체, 이의 제조방법 및 이를 이용한 아미노피리미딘 유도체의 제조방법
Registered · 2018-07 · Application 1020180086377
프로테인 카이네이즈에 대한 선택적 억제제의 합성에 유용한 중간체 및 이의 제조방법
Registered · 2018-07 · Application 1020180086378
(E)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
Withdrawn · 2018-07 · Application 1020180076969
다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
Registered · 2018-05 · Application 1020180057088
이중 작용 단백질 및 그의 유도체의 제조방법
Registered · 2018-04 · Application 1020180045941
아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법
Registered · 2018-04 · Application 1020180044850
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
TW · Registered · 2018-04 · Application 107113234
신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2018-03 · Application 1020180032548
신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2018-03 · Application 1020180032554
SUSTAINED RELEASE TABLET COMPRISING PREGABALIN THROUGH TWO-PHASE RELEASE-CONTROLLING SYSTEM
US · Published · 2018-01 · Application 15882390
클로피도그렐 및 로수바스타틴을 포함하는 이중층 정제의 제조방법
Registered · 2017-11 · Application 1020170150491
융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
Registered · 2017-11 · Application 1020170149338
Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
US · Registered · 2017-11 · Application 16348249
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS, HEPATIC FIBROSIS, AND HEPATIC CIRRHOSIS COMPRISING FUSION PROTEINS
EP · Registered · 2017-11 · Application 17870009.2
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS, HEPATIC FIBROSIS, AND HEPATIC CIRRHOSIS COMPRISING FUSION PROTEINS
PCT · Published · 2017-11 · Application PCT/KR2017/012726
呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物
JP · Registered · 2017-07 · Application 29134539
퀴나졸린 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
Registered · 2017-04 · Application 1020170053608
CCL3変異体を含む融合タンパク質およびその用途
JP · Registered · 2017-04 · Application 30555968
베이킹 소다를 함유하는 칫솔모 및 그 칫솔모를 포함하는 칫솔
Rejected · 2017-03 · Application 1020170028540
PD-L1에 결합하는 항원 결합 단백질
Registered · 2017-01 · Application 1020187024978
PD-L1에 결합하는 항원 결합 단백질
Published · 2017-01 · Application 1020267004206
피페라실린 또는 그의 염 및 타조박탐 또는 그의 염을 포함하는 동결건조제제
Withdrawn · 2017-01 · Application 1020170009091
메트포르민 및 HMG-CoA 환원효소 억제제를 포함하는 정제
Registered · 2016-12 · Application 1020160163660
구강용품을 위한 접철식 포장 케이스
Registered · 2016-11 · Application 1020160155929
클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법
Registered · 2016-11 · Application 1020160150385
Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same
US · Registered · 2016-10 · Application 15768865
Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same
US · Registered · 2016-10 · Application 15768616
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP · Registered · 2016-10 · Application 20179208.2
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP · Registered · 2016-10 · Application 16860300.9
DUAL FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP · Published · 2016-10 · Application 25151368.5
DUAL FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
EP · Registered · 2016-10 · Application 16860306.6
DUAL FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
PCT · Published · 2016-10 · Application PCT/KR2016/012300
LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
PCT · Published · 2016-10 · Application PCT/KR2016/012288
벤조[d]싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Registered · 2016-07 · Application 1020160086957
CCL3 변이체를 포함하는 융합 단백질 및 이의 용도
Registered · 2016-04 · Application 1020160053018
염증성 질환 또는 통증 예방 또는 치료용 조성물
Registered · 2016-04 · Application 1020160045648
CD47에 결합하는 항체 치료제
Registered · 2016-03 · Application 1020247000720
CD47에 결합하는 항체 치료제
Registered · 2016-03 · Application 1020177028115
Antibody therapeutics that bind cd47
TW · Registered · 2016-03 · Application 111131339
베이킹 소다를 함유하는 칫솔모를 포함하는 칫솔
Registered · 2015-11 · Application 1020150156450
지속형 FGF21 융합 단백질 및 이를 포함하는 약학적 조성물
Registered · 2015-10 · Application 1020150150574
이중 작용 단백질 및 이를 포함하는 약학적 조성물
Registered · 2015-10 · Application 1020150150576
EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
Published · 2015-10 · Application 1020247013986
EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
Registered · 2015-10 · Application 1020177012969
EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
Registered · 2015-10 · Application 1020207002949
EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
Registered · 2015-10 · Application 1020217002019
EGFR 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
Registered · 2015-10 · Application 1020237000623
Compounds and compositions for modulating egfr mutant kinase activities
TW · Registered · 2015-10 · Application 108118264
Compounds and compositions for modulating egfr mutant kinase activities
TW · Registered · 2015-10 · Application 104133539
COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
EP · Published · 2015-10 · Application 25220748.5
COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES
EP · Registered · 2015-10 · Application 24166947.2
EGFR変異型キナーゼ活性をモジュレートするための化合物および組成物
JP · Registered · 2015-10 · Application 29519685
콜린 알포세레이트-함유 정제 및 이의 제조방법
Registered · 2015-08 · Application 1020150118648
황칠 나무 추출물을 함유하는 간 기능 개선용 조성물
Registered · 2015-05 · Application 1020150075074
Subsidiary: (주)에이투젠Lactobacillus plantarum HAC01 strain having anti-inflammatory efficacy and metabolic disease alleviating efficacy and use thereof
CN · Published · 2015-05 · Application 201580041507.4
Subsidiary: (주)에이투젠Lanctobacillus plantarum HAC01 strain having anti-inflammatory efficacy and metabolic disease alleviating efficacy and use thereof
US · Registered · 2015-05 · Application 15314694
Subsidiary: (주)에이투젠HAC01 STRAIN HAVING ANTI-INFLAMMATORY EFFICACY AND METABOLIC DISEASE ALLEVIATING EFFICACY AND USE THEREOF
PCT · Published · 2015-05 · Application PCT/KR2015/005296
지속형 FGF21 융합 단백질 및 이를 포함하는 약학적 조성물
Withdrawn · 2015-01 · Application 1020150008022
호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물
Registered · 2014-07 · Application 1020167002234
呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物
JP · Published · 2014-07 · Application 28523670
ピリミジン環を含む二環式誘導体及びその製造方法
JP · Published · 2014-05 · Application 28515278
피롤로[2,3-c]피리딘 유도체 또는 이의 약학적으로 허용가능한 염의 제조방법
Expired · 2014-05 · Application 1020140059473
피롤로[2,3-c]피리딘 유도체 또는 이의 약학적으로 허용가능한 염의 제조방법
Expired · 2014-05 · Application 1020140053913
신규의 트라이아졸론 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Registered · 2014-04 · Application 1020140047814
新規トリアゾロン誘導体またはその塩、およびそれを含む医薬組成物
JP · Published · 2014-04 · Application 28510612
황칠 나무 추출물을 함유하는 숙취해소 및 예방용 조성물
Registered · 2013-11 · Application 1020130147613
퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물
Expired · 2013-07 · Application 1020130086476
퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물
Expired · 2013-07 · Application 1020130086473
피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
Registered · 2013-05 · Application 1020130058843
클로피도그렐과 아스피린을 포함하는 약학 조성물 및 그의 제조방법
Registered · 2013-03 · Application 1020130023744
신규의 헤테로아릴을 포함하는 페녹시벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
Withdrawn · 2013-01 · Application 1020130005128
신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법
Withdrawn · 2013-01 · Application 1020130005076
4,5-다이하이드로-1H-피라졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Registered · 2012-10 · Application 1020120119077
4,5-다이하이드로-1H-피라졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Registered · 2012-10 · Application 1020120119067
피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
Registered · 2012-10 · Application 1020120116373
이미드를 포함하는 벤조싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2012-09 · Application 1020120105456
페닐이미드를 포함하는 벤조싸이아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2012-09 · Application 1020120105453
이미드를 포함하는 바이싸이클릭 아졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
Withdrawn · 2012-09 · Application 1020120105462
PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US · Published · 2012-09 · Application 14346506
フェニルイミドを含むベンゾチアゾール誘導体またはその塩及びそれを含む医薬組成物
JP · Published · 2012-09 · Application 26531726
비스포스폰산 또는 그의 염을 함유하는 경구용 약학 조성물
Withdrawn · 2012-07 · Application 1020120080787
2상 방출-제어 시스템에 의한 프레가발린을 함유하는 서방성 정제
Registered · 2012-07 · Application 1020120079177
반코마이신 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
Withdrawn · 2012-07 · Application 1020120076674
레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
Registered · 2012-03 · Application 1020120031411
다이아미노피리미딘 유도체 및 그의 제조방법
Registered · 2012-02 · Application 1020120018926
다이아미노피리미딘 유도체 및 그의 제조방법
Registered · 2012-02 · Application 1020120018933
PHARMACEUTICAL COMPOSITIONS COMPRISING REVAPRAZAN-CONTAINING NANOPARTICLES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2012-02 · Application PCT/KR2012/000600
프로-페놀옥시다아제 시스템을 활성화시키는 단백질 및 이를 코딩하는 유전자
Expired · 2011-07 · Application 1020110074850
HMG-CoA 환원효소 억제제 및 그의 중간체의 제조방법
Registered · 2011-06 · Application 1020110064359
레바프라잔 또는 그의 염을 함유하는 현탁액 형태의 경구투여용 약학 조성물
Registered · 2011-05 · Application 1020110048176
프로-페놀옥시다아제 시스템을 활성화시키는 단백질 및 이를 코딩하는 유전자
Expired · 2011-03 · Application 1020110021826
프로-페놀옥시다아제 시스템을 활성화시키는 단백질 및 이를 코딩하는 유전자
Expired · 2011-03 · Application 1020110021829
다이아미노피리미딘 유도체 및 그의 제조방법
Registered · 2011-02 · Application 1020110016986
레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
Registered · 2011-02 · Application 1020110012426
레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물
Registered · 2010-12 · Application 1020100121580
레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
Registered · 2010-12 · Application 1020100121588
테르비나핀 또는 그의 염을 함유하는 국소 항진균 조성물
Rejected · 2010-11 · Application 1020100117268
신규의 글루코키나제 활성화제 및 그의 제조방법
Expired · 2010-09 · Application 1020100091621
피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
Expired · 2010-04 · Application 1020100030063
선복화 추출물로부터 분리된 화합물을 유효성분으로 함유하는 염증 또는 알러지 질환의 예방 및 치료용 조성물
Expired · 2010-01 · Application 1020100006868
피리미딘 유도체의 제조방법
Withdrawn · 2009-12 · Application 1020090130488
종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
Withdrawn · 2009-11 · Application 1020090112718
신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트
Expired · 2009-11 · Application 1020090106308
조루증 치료를 위한 경구용 의약 조성물
Registered · 2009-05 · Application 1020090043643
2-메틸-2'-페닐프로피온산 유도체의 제조 방법 및 이에 사용되는 신규한 중간체 화합물
Expired · 2009-02 · Application 1020090011388
항 DR4 단일클론항체 및 이를 포함하는 암 예방 또는 치료용 조성물
Rejected · 2008-09 · Application 1020080093436
퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
Rejected · 2008-03 · Application 1020080021695
ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体, その方法およびそれを含む医薬組成物
JP · Published · 2008-03 · Application 21552595
PROTEINS ACTIVATING PRO-PHENOLOXIDASE SYSTEM AND GENES ENCODING THE SAME
EP · Registered · 2008-02 · Application 08712316.2
펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트
Expired · 2007-12 · Application 1020070140064
레바프라잔 함유 고체분산체 및 그의 제조방법
Registered · 2007-12 · Application 1020070135270
히알루론산 또는 그의 염, 금속이온, 및 수-난용성생분해성 고분자를 포함하는 표적지향을 위한 나노입자 및그의 제조방법
Withdrawn · 2007-10 · Application 1020070106434
펩티도글리칸 인식 신호 전달에 관여하는 단백질, 이를코딩하는 유전자, 및 이를 포함하는 박테리아 감염 검출용키트
Expired · 2007-09 · Application 1020070095196
옥살리플라틴-함유 주사용 용액
Registered · 2007-09 · Application 1020070092917
도네페질 또는 그의 제조용 중간체의 제조방법
Expired · 2007-08 · Application 1020070080674
세푸록심 악세틸 함유 과립 및 그의 제조방법
Registered · 2007-07 · Application 1020070068560
프로-페놀옥시다아제 시스템을 활성화시키는 단백질 및이를 코딩하는 유전자
Expired · 2007-02 · Application 1020070013231
고지혈증 및/또는 고혈압에 기인한 발기부전 예방 또는치료용 약학 조성물
Expired · 2006-12 · Application 1020060138262
표적지향을 위한 나노입자 및 그의 제조방법
Expired · 2006-12 · Application 1020060120799
위장관 점막 손상의 예방 또는 치료용 조성물
Registered · 2006-11 · Application 1020060118161
プランルカストを含有する噴霧-乾燥顆粒およびその製造方法
JP · Registered · 2006-09 · Application 18269305
헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
Expired · 2006-09 · Application 1020060090367
안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물
Registered · 2006-09 · Application 1020060085005
필름코팅용 조성물
Registered · 2006-08 · Application 1020060082029
신규 페닐프로판산 유도체, 이의 제조방법 및 이를함유하는 퍼옥시좀 증식자-활성화 수용체 효능제
Withdrawn · 2006-07 · Application 1020060066440
메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
Registered · 2006-06 · Application 1020060060103
갈색거저리 유충의 체액으로부터 펩티도글리칸 인식단백질을 분리하는 방법
Expired · 2006-01 · Application 1020087017565
인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
Expired · 2005-12 · Application 1020050133266
분무-건조 과립 및 그의 제조방법
Expired · 2005-10 · Application 1020050102488
프란루카스트를 함유하는 과립 및 그의 제조방법
Expired · 2005-10 · Application 1020050102489
신규의 2-페닐피리미딘 유도체 및 그의 제조방법
Expired · 2005-10 · Application 1020050101634
신규의 테트라하이드로피리딘 유도체 및 그의 제조방법
Expired · 2005-10 · Application 1020050101633
프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
Expired · 2005-09 · Application 1020050091995
피롤로[3,2-c]피리딘 유도체 및 그의 제조방법
Expired · 2005-09 · Application 1020050082009
피롤로[3,2-c]피리딘 유도체 및 그의 제조방법
Expired · 2005-09 · Application 1020050082008
피롤로[3,2-b]피리딘 유도체 및 그의 제조방법
Expired · 2005-09 · Application 1020050082010
피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
Expired · 2005-09 · Application 1020050082011
피롤로[2,3-c]피리딘 유도체 및 그의 제조방법
Expired · 2005-09 · Application 1020050082012
PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
EP · Registered · 2005-09 · Application 05808482.3
PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
EP · Registered · 2005-09 · Application 05808813.9
PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
EP · Registered · 2005-09 · Application 05808479.9
PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
EP · Registered · 2005-09 · Application 05781131.7
PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2005-09 · Application PCT/KR2005/002926
PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2005-09 · Application PCT/KR2005/002924
PYRROLO[2,3-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2005-09 · Application PCT/KR2005/002928
PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2005-09 · Application PCT/KR2005/002927
PYRROLO[3,2-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 2005-09 · Application PCT/KR2005/002925
PROCESS FOR PURIFICATION OF CILOSTAZOL
PCT · Published · 2005-08 · Application PCT/KR2005/002676
디클라주릴-함유 약제학적 조성물의 제조방법
Registered · 2005-07 · Application 1020050069969
시부트라민을 함유하는 약제학적 조성물
Expired · 2005-07 · Application 1020050062572
피롤로피리딘 유도체를 포함하는 항암제 조성물
Expired · 2005-06 · Application 1020050055909
아목시실린 및/또는 클라불란산 또는 이의 염을 함유하는경구용 현탁정제 조성물
Expired · 2005-06 · Application 1020050052202
신규 탈할로겐화제를 이용한 슈도-아미노슈가의 제조방법
Expired · 2005-05 · Application 1020050044964
HUMANIZED ANTIBODY AGAINST S-SURFACE ANTIGEN OF HEPATITIS B VIRUS
PCT · Published · 2005-04 · Application PCT/KR2005/001038
신규한 3-케토발리독실아민 C-N 라이에이즈 유전자
Expired · 2005-03 · Application 1020050025810
신규한 베타-글루코시데이즈 유전자
Expired · 2005-03 · Application 1020050025811
신규의 이미다조[1,2-a]피리딘 유도체 및 그의 제조방법
Expired · 2005-03 · Application 1020050019499
신규의 5,6-다이메틸피리미딘 유도체 및 그의 제조방법
Expired · 2005-03 · Application 1020050019502
피롤로[2,3-d]피리다진 유도체 및 그의 제조방법
Expired · 2005-03 · Application 1020050019500
퍼옥시좀 증식자-활성화 수용체를 활성화하는 신규 화합물,이의 제조방법 및 이를 함유하는 퍼옥시좀 증식자-활성화수용체 효능제
Withdrawn · 2005-02 · Application 1020050016715
4-(4-플루오르페닐)-2-이소부티릴-3-페닐-4-옥소-N-페닐-부틸아미드의 신규한 제조방법
Expired · 2004-12 · Application 1020040117954
신규한 스트렙토마이세스 속 YA1766 균주
Expired · 2004-12 · Application 1020040117958
광학 활성 디올 유도체의 신규 제조방법
Expired · 2004-12 · Application 1020040117957
AN ANTIBODY VARIABLE REGION OF A MONOCLONAL ANTIBODY AGAINST HUMAN TUMOR NECROSIS FACTOR ALPHA AND A GENE ENCODING THE SAME
EP · Registered · 2004-11 · Application 04800099.6
신규한 6-[4-(1-시클로헥실-1H-테트라졸-5-일)부톡시]-3,4-디히드로-2(1H)-퀴놀리논 정제방법
Expired · 2004-08 · Application 1020040067010
고순도의 레보플록사신 제조방법
Expired · 2004-07 · Application 1020040056637
속효성의 항진균 외용약제 조성물
Expired · 2004-07 · Application 1020040054823
캔디다 알비칸스의 이형전환과 병원성에 관련된 신규의유전자 CaLAG1
Expired · 2004-04 · Application 1020040028338
캔디다 알비칸스의 이형전환과 병원성에 관련된 신규의유전자 CaMOB2
Rejected · 2004-04 · Application 1020040028329
하이드로코티손 또는 그 염을 함유하는 나노에멀젼 조성물
Expired · 2004-04 · Application 1020040027791
B형 간염바이러스의 S-표면항원을 인식하는 인간화 항체및 이의 제조방법
Expired · 2004-04 · Application 1020040025573
인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
Expired · 2003-11 · Application 1020030080950
면역크로마토그래피법을 이용한 전립선암 및 전립선비대증 진단용 키트
Expired · 2003-11 · Application 1020030080300
겐타마이신 Β 생산균주 및 이를 이용한 겐타마이신 Β의 제조방법
Expired · 2003-10 · Application 1020030073164
카바졸온 유도체 제조 방법
Expired · 2003-10 · Application 1020030072096
카바졸온 유도체 제조 방법
Expired · 2003-10 · Application 1020030072098
카바졸온 유도체의 제조방법
Expired · 2003-10 · Application 1020030072099
암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
Expired · 2003-10 · Application 1020030069806
1-페닐피페리딘-3-온 유도체 및 그의 제조방법
Expired · 2003-07 · Application 1020030051574
염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
Expired · 2003-04 · Application 1020030026723
철분함유 고밀도 펠렛 조성물 및 이의 제조방법
Expired · 2003-04 · Application 1020030024015
씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
Expired · 2003-03 · Application 1020030014622
씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
Expired · 2003-03 · Application 1020030014620
분통
Expired · 2003-02 · Application 2020030005857
신약탐색용 단백질 칩 및 이를 이용한 신약탐색방법
Withdrawn · 2002-12 · Application 1020020087866
비형간염바이러스의 에스-표면항원을 인식하는 인간화항체 및 이의 제조방법
Withdrawn · 2002-12 · Application 1020020084949
퀴놀론 카르복실레이트 유도체의 제조방법
Expired · 2002-12 · Application 1020020082222
항체 중쇄 발현벡터
Expired · 2002-08 · Application 1020020045765
항체 경쇄 카파 발현벡터
Expired · 2002-08 · Application 1020020045768
항체 경쇄 람다 발현벡터
Expired · 2002-08 · Application 1020020045767
A VARIABLE REGION OF THE MONOCLONAL ANTIBODY AGAINST THE HBV S-SURFACE ANTIGEN AND A GENE ENCODING THE SAME
PCT · Published · 2002-05 · Application PCT/KR2002/000905
C형 간염 억제제 N-아미노피롤리딘
Withdrawn · 2002-04 · Application 1020020022106
이미다졸 유도체의 제조방법
Expired · 2002-02 · Application 1020020007231
Subsidiary: (주)네오딘바이오벳알티 피시알에 의한 디스템퍼 바이러스검출용 키트 및 그검출 방법
Rejected · 2002-01 · Application 1020020004112
터비나핀 또는 그의 염산염의 제조방법
Expired · 2001-12 · Application 1020010086713
베타-디-리보푸라노즈 유도체의 제조방법
Expired · 2001-12 · Application 1020010076802
4-페닐-3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
Expired · 2001-07 · Application 1020010045321
3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
Expired · 2001-07 · Application 1020010045318
4-아미노-3-사이클로부텐-1,2-다이온 유도체 및 그의제조방법
Expired · 2001-07 · Application 1020010045317
3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
Expired · 2001-07 · Application 1020010045319
4-페닐-3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
Expired · 2001-07 · Application 1020010045320
A VARIABLE REGION OF THE MONOCLONAL ANTIBODY AGAINST THE HBV S-SURFACE ANTIGEN AND A GENE ENCODING THE SAME
EP · Registered · 2001-05 · Application 01936990.9
A VARIABLE REGION OF THE MONOCLONAL ANTIBODY AGAINST THE HBV S-SURFACE ANTIGEN AND A GENE ENCODING THE SAME
PCT · Published · 2001-05 · Application PCT/KR2001/000894
비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
Expired · 2001-05 · Application 1020010026634
인간 에리트로포이에틴의 제조방법
Expired · 2001-05 · Application 1020010026636
인간 융모막 성선자극 호르몬의 정제방법
Expired · 2000-08 · Application 1020000049963
라스 변이세포의 성장을 억제하는 티오우레아 및이소티오우레아 유도체
Expired · 2000-07 · Application 1020027001065
비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
Expired · 2000-05 · Application 1020000028938
경구용 속붕해정 및 그의 제조방법
Rejected · 2000-03 · Application 1020000014170
로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
Expired · 2000-02 · Application 1020000007697
4-하이드록실아미노-3-사이클로부텐-1,2-다이온 유도체 및이들의 제조 방법
Expired · 2000-02 · Application 1020000004835
4-하이드라지노-3-사이클로부텐-1,2-다이온 유도체 및이들의 제조 방법
Expired · 2000-02 · Application 1020000004836
아버멕틴의 정제방법
Expired · 1999-10 · Application 1019990047368
신규의 스트렙토마이세스 아버미틸리스 변이주 및 아버멕틴의 제조방법
Expired · 1999-10 · Application 1019990047367
라스 변이세포의 성장을 억제하는 티오우레아 유도체 또는 이들의 무독성염
Withdrawn · 1999-07 · Application 1019990031188
활성형의 재조합 인체 과립성 백혈구 콜로니 자극인자의 정제방법
Expired · 1999-06 · Application 1019990021065
아제티디논 유도체의 제조방법
Withdrawn · 1999-05 · Application 1019990019124
베타-메틸 아제티디논 유도체의 제조방법
Withdrawn · 1999-05 · Application 1019990019125
하이드라진 유도체 및 그의 제조방법
Expired · 1999-04 · Application 1019990014330
신규의 피리미딘 유도체 및 그의 제조방법
Expired · 1998-11 · Application 1019980049164
겔여과컬럼크로마토그래피를이용한봉입체형태의인체과립성백혈구콜로니자극인자의재생방법
Expired · 1998-09 · Application 1019980040784
라스변이세포의성장을억제하는티오우레아유도체또는이들의무독성염
Expired · 1998-09 · Application 1019980037260
4-시아노메칠이미다졸의분리방법
Expired · 1998-08 · Application 1019980033692
라스변이세포성장억제구아니딘유도체
Expired · 1998-07 · Application 1019980028069
인체 과립구 콜로니 자극인자의 유전자, 재조합 벡터 및 형질 전환체 및 그들을 이용한 인체 과립구 콜로니 자극인자의 제조방법
Expired · 1998-07 · Application 1019980027475
1-브로모에틸 아세테이트의 제조방법
Expired · 1998-05 · Application 1019980019129
세파클러함유서방성정제
Expired · 1998-04 · Application 1019980011397
신규의피리미딘유도체및그의제조방법
Expired · 1998-03 · Application 1019980010754
NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
PCT · Published · 1998-03 · Application PCT/KR1998/000058
2-(2-아미노티아졸-4-일)-2-신-(2-티-부톡시카보닐메톡시이미노)아세트산의제조방법
Expired · 1998-03 · Application 1019980007188
단일클론항체의 등전점에 따른 항체 결합 라텍스 제조 방법
Expired · 1997-12 · Application 1019970077538
유사펩타이드유도체,이들의제조방법및이들을유효성분으로함유하는라스변이세포성장억제조성물
Expired · 1997-12 · Application 1019970077539
무정형 세푸록심 악세틸의 제조방법
Expired · 1997-08 · Application 1019970037144
결정형 세푸록심 악세틸의 제조방법
Expired · 1997-08 · Application 1019970037143
유사 펩타이드 유도체, 이들의 제조방법 및 이들을 유효성분으로 함유하는 라스 변이세포 성장억제 조성물
Expired · 1997-05 · Application 1019970021244
유사 펩타이드 유도체, 이들의 제조방법 및 이들을 유효성분으로 함유하는 라스 변이세포 성장억제 조성물
Expired · 1997-05 · Application 1019970021243
1-メチル-1,2,3,4-テトラヒドロイソキノリンの製造方法
JP · Published · 1997-04 · Application 12198538
봉입체 형태의 인체 과립성 백혈구 콜로니 자극인자의 재생방법
Expired · 1997-04 · Application 1019970014350
투명액상 이부프로펜 조성물 및 이를 함유하는 연질캅셀제
Expired · 1997-03 · Application 1019970009001
(R)-피리미딘 유도체의 제조방법
Expired · 1996-10 · Application 1019960049381
피리미딘 유도체의 제조방법
Expired · 1996-10 · Application 1019960049382
(S)-피리미딘 유도체의 제조방법
Expired · 1996-10 · Application 1019960049380
Use of isopropyl-2-(1,3-dithietan-2-ylidene)-2-(N-(4-methylthiazol-2-yl) carbamoyl)acetate as a cancer chemopreventive agent
EP · Published · 1996-10 · Application 1996116343
결명자. 오미자 함유 복합 음료 조성물
Rejected · 1996-08 · Application 1019960033858
터부탈린설페이트-구아이페네신 서방성 복합제제 (2)
Expired · 1996-06 · Application 1019960020515
터부탈린설페이트-구아이페네신 서방성 복합제제 (1)
Expired · 1996-06 · Application 1019960020514
피리미딘 유도체의 제조방법
Expired · 1996-05 · Application 1019960014538
7-아미노-3-세펨-4-카르복실산의 제조방법
Rejected · 1996-05 · Application 1019960014537
신규의 피리미딘 유도체 및 그의 제조방법
Expired · 1996-05 · Application 1019960014539
인체 과립성 백혈구 콜로니 자극인자를 코딩하는유전자
Expired · 1996-04 · Application 1019960012987
USE OF THIOKETENE DERIVATIVES FOR PREVENTING OR TREATING HEPATITIS B
PCT · Published · 1996-04 · Application PCT/KR1996/000056
화학적발암억제제
Expired · 1995-10 · Application 1019950035537
7-아미노-3-클로로-3-세펨-4-카르복실산의제조방법
Rejected · 1995-08 · Application 1019950024769
사이클로스포린A함유조성물및그의제조방법
Expired · 1995-05 · Application 1019950013737
B형바이러스성감염의예방및치료용약학적제제
Expired · 1995-04 · Application 1019950010214
투명액상감기약조성물및이를함유하는연질캅셀제
Rejected · 1995-03 · Application 1019950006014
도코사헥사엔산함유수용액조성물
Rejected · 1995-03 · Application 1019950006013
리파마이신유도체의제조방법
Expired · 1994-12 · Application 1019940039201
사이클로스포린함유액제조성물
Expired · 1994-11 · Application 1019940031131
테르페나딘-염산슈도에페드린의다층펠렛조성물
Rejected · 1994-11 · Application 1019940029972
고상면역크로마토그래피에의한임신진단장치
Expired · 1994-10 · Application 1019940025307
단일클론항제가결합된라텍스의제조방법
Expired · 1994-09 · Application 1019940022352
안지오텐신II차단효과를가지는인돌유도체
Rejected · 1994-08 · Application 1019940020081
신규의피리미딘유도체및그의제조방법
Expired · 1994-08 · Application 1019940019997
신규의피리미딘유도체및그의제조방법
Expired · 1994-08 · Application 1019940019998
테르페나딘함유펠렛조성물
Expired · 1994-08 · Application 1019940019999
테르페나딘과염산슈도에페드린복합펠렛조성물
Rejected · 1994-08 · Application 1019940020000
프로폴리스함유치약조성물
Rejected · 1994-07 · Application 1019940016921
7-아미노-3-클로로세펨-4-카르복실산의제조방법
Rejected · 1994-06 · Application 1019940013196
세팔로스포린중간체의제조방법
Expired · 1994-06 · Application 1019940013197
트리아졸유도체및그의제조방법
Rejected · 1994-06 · Application 1019940012285
세팔로스포린유도체및이의염의제조방법
Rejected · 1994-06 · Application 1019940012286
세팔로스포린유도체및이의염의제조방법
Rejected · 1994-06 · Application 1019940012287
사이클로스포린함유액제조성물
Expired · 1994-06 · Application 1019940012289
에스트라디올의경피흡수제제조성물
Rejected · 1994-05 · Application 1019940010698
에스트라디올의지속성경피흡수제제
Rejected · 1994-05 · Application 1019940010697
프로폴리스함유피부용세정제
Rejected · 1994-03 · Application 1019940006732
트리아졸유도체및그의제조방법
Rejected · 1994-03 · Application 1019940004918
트리아졸유도체및그의제조방법
Rejected · 1994-03 · Application 1019940004917
3-비닐세팔로스포린산유도체의제조방법
Expired · 1994-03 · Application 1019940004265
비듬제거용샴푸조성물
Rejected · 1994-02 · Application 1019940003268
신규의퀴나졸린유도체및그의제조방법
Expired · 1993-10 · Application 1019930021877
세팔로스포린유도체및그의제조방법
Expired · 1993-09 · Application 1019930017578
세팔로스포린유도체및그의제조방법
Expired · 1993-09 · Application 1019930017579
고분자량-우로가스트론의정제방법
Expired · 1993-07 · Application 1019930014841
저분자량-우로가스트론의정제방법
Expired · 1993-07 · Application 1019930014842
당뇨병성또는노인성(당)백내장예방치료제
Expired · 1993-07 · Application 1019930013097
지속성경비흡수제제및그의제조방법
Rejected · 1993-04 · Application 1019930006780
유로키나제의정제방법
Rejected · 1993-02 · Application 1019930001356
약액주머니자동공급방법및장치
Expired · 1993-01 · Application 1019930000720
발효에의한네브라마이신팩터5'제조방법
Expired · 1992-09 · Application 1019920017344
뇨 수거단계에서뇨중유용단백질의포집방법
Rejected · 1992-09 · Application 1019920016701
가용화프로폴리스조성물
Expired · 1992-08 · Application 1019920014532
신규의항진균제조성물
Rejected · 1992-07 · Application 1019920013789
신규미생물슈도모나스에루기노사와이를이용한네브라마이신펙터정량방법
Expired · 1992-02 · Application 1019920002512
디옥솔유도체
Withdrawn · 1991-10 · Application 1019910017835
3-피라진유도체치환된세팔로스포린화합물
Withdrawn · 1991-05 · Application 1019910007082
지속성세팔렉신과립제의제조방법
Expired · 1991-03 · Application 1019910004839
1,4-디하이드로피리딘카복실산유도체및그의제조방법
Expired · 1990-07 · Application 1019900010929
1,4-디하이드로피리딘유도체
Expired · 1990-07 · Application 1019900010930
지속성세팔렉신과립제의제조방법
Withdrawn · 1990-05 · Application 1019900006809
항진균성겔제
Expired · 1990-05 · Application 1019900006810
1,4-디하이드로피리딘유도체및그의제조방법
Rejected · 1989-10 · Application 1019890015314
신규1,4-디히드로-4-옥소퀴놀린유도체
Expired · 1989-09 · Application 1019890013698
3-퀴녹살린디온일새팔로스포린화합물
Rejected · 1989-06 · Application 1019890008520
살리실산메칠,L-멘톨,DL-캄파등의휘발성물질을다량함유한크림제의조성및제법
Expired · 1989-04 · Application 1019890005144
1,4-디하이드로피리딘유도체및그의제조방법
Expired · 1988-10 · Application 1019880014022
티오케텐유도체와그의제조방법
Expired · 1988-10 · Application 1019880014023
1,4-디하이드로피리딘유도체및그의제조방법
Rejected · 1988-10 · Application 1019880014021
장용성과립제의제조방법
Rejected · 1988-06 · Application 1019880006652
플라스틱용기
Rejected · 1988-05 · Application 2019880007584
1,4-디하이드로피리딘카복실산의제조방법
Expired · 1988-04 · Application 1019880004416
복합필기구
Expired · 1988-02 · Application 1019880001876
2-티오히단토인유도체와제조방법
Expired · 1987-11 · Application 1019870012361
1,3-디티올-2-일리덴유도체와그의제조방법
Expired · 1987-07 · Application 1019870006745
2-(7'-테오필린메틸)-1,3-디옥소란의제조방법
Expired · 1986-12 · Application 1019860011246
인삼연조엑기스등을함유한연질캅셀제조방법
Rejected · 1986-09 · Application 1019860007920
세라티아펩티다제의생산방법
Expired · 1986-07 · Application 1019860006287
벤조티아진디옥사이드류의제조방법
Rejected · 1986-03 · Application 1019860001556
말론산유도체의제조방법
Expired · 1984-07 · Application 1019840004226
7-(디(-)-알파-(4-알킬-2,3-디옥소-1-피페라진카복시아미드)-알파-페닐(또는하이드록시페닐)아세트아미도)-3-치환---제조방
Rejected · 1984-05 · Application 1019840002423
7-아미노-3-(5-메틸-1,3,4-티아디아졸-2-일)티오메틸-3-세펨-4-카르복실산의제조방법
Expired · 1984-03 · Application 1019840001279
신포접화합물의제조방법
Expired · 1984-02 · Application 1019840000779
1-(4-클로로벤조일)-5-메톡시-2-메틸-3인돌초산에스테르의제조방법
Expired · 1984-02 · Application 1019840000616
3-인돌아세토히드록사믹산유도체의제조방법
Expired · 1984-01 · Application 1019840000398
감초성분이함유된유산균음료의제조방법
Expired · 1983-09 · Application 1019830004348
3,4-디하이드로-2H-1,2-벤조티아진-카복실산-1,1-디옥사이드류의제조방법
Expired · 1983-03 · Application 1019830001019
리신알-옥소-4-바이페닐부칠산유도체의제조방법
Rejected · 1983-02 · Application 1019830000390
태반성성선자극호르몬의정제방법
Rejected · 1983-01 · Application 1019830000101
(1,1'-비페닐)-알-옥소부타노의산피-아세트아미노페놀에스테르유도체의제조방법
Rejected · 1983-01 · Application 1019830000100
3-(4-페닐벤조일)-프로피온산유도체의제조방법
Expired · 1982-10 · Application 1019820004507
B-락탐계항생물질의제조방법
Rejected · 1980-05 · Application 1019800001873
싸이폰식연속추출장치에의한인삼유효성분추출방법
Expired · 1971-08 · Application 1019710001226
약품을함유하는제라친제구형과립제조방법
Expired · 1967-01 · Application 1019670000034

AI reads

MAA server logs · IP-verified

133

Times AI engines pulled YUHAN CORPORATION's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

130

Index crawls

Collected as raw material for future answers.

Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

live 0

Last 7 days

101

live 1

Last 30 days

132

live 2

All time

OpenAIChatGPT-Userlive2
OpenAIOAI-SearchBot116
GoogleGoogleOther7
PerplexityPerplexityBot4
AnthropicClaudeBot2
MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for YUHAN CORPORATION and every listed Korean medical, bio and AI company.

How to connect (MCP)

Not yet compiled: business overview. Send us materials and we will add them

Company facts

Founded: 1926
Listed: 1962
Market: KOSPI 000100
CEO: 대표이사 조욱제
Location: Seoul
Category: Pharma & CDMO

Performance

Consolidated · DART

Year	Revenue	Op. profit
2025	₩2186.6B	₩104.4B
2024	₩2067.8B	₩54.9B
2023	₩1859.0B	₩57.0B

AI visibility

2026-10-01

35/ 100

✓Crawler access

✗Structured data

✗Sitemap

✓HTTPS

✓English pages

✗llms.txt

Keywords

pharmaceuticalsleclazainnovative-druglicense-outhousehold-productsveterinary-medicinekorea

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

SHINHUNG CO.,LTD25 shared

Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.

DENTIS CO.,LTD24 shared

Founded in 2016 and listed on KOSDAQ in 2017, DENTIS manufactures dental implants, medical LED lighting, and dental 3D printers.

DIO Corporation20 shared

DIO Corporation, established in 1988 and listed on KOSDAQ in 2000, manufactures and sells dental implants.

Corentec Co., Ltd.14 shared

Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.

CG MedTech Co.,Ltd.14 shared

Founded in 1997 and KOSDAQ-listed in 2015, CG MedTech makes orthopedic medical devices and also operates an electric energy business.

Alpha AI Co.,Ltd.13 shared

Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.

MEDYSSEY CO.,LTD10 shared

Manufactures spinal implants and metal 3D-printed patient-specific implants, exporting to over 25 countries.

WSI Co., Ltd.7 shared

Founded and KOSDAQ-listed in 2018, WSI distributes spine/joint devices and has expanded into medical robots and pharma via subsidiaries.

OSTEONIC Co., Ltd.7 shared

Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.

Organ Eco Tech Co.,Ltd.7 shared

Organ Eco Tech, founded in 2006 and KONEX-listed in 2016, manufactures spinal implants.

CELLUMED CO., LTD.7 shared

KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.

L&K BIOMED CO., LTD.6 shared

Spinal implant device maker founded 2008, listed on KOSDAQ 2016; produces Cervical and Thoraco Lumbar Cage, Screw, and Plate products.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
Approvals & clinical trials: Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures: KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials: ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials: DART corporate disclosure filings — annual
Publications: PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents: KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads: Our server logs, IP-verified every 6 hours
AI visibility: Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition